The role of NCAM signaling and its effector protein, [beta]1-integrin, in tumor progression by Kren, Angelika
  I
 
The role of NCAM signaling and its effector protein,  















Erlangung der Würde eines Doktors der Philosophie  
vorgelegt der  
Philosophisch-Naturwissenschaftlichen Fakultät  























  II 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät  
auf Antrag von  
 
Prof. G. Christofori 
Prof. A. Rolink 






Basel, den 4. Juli 2006 
 
 
      Prof. Dr. Hans-Jakob Wirz 
      Dekan  
Table of contents 
 I
Table of contents 
TABLE OF CONTENTS ................................................................................................................................... I 
SUMMARY ................................................................................................................................................. IV 
ZUSAMMENFASSUNG .................................................................................................................................. V 
1. GENERAL INTRODUCTION ............................................................................................................ 1 
1.1. CANCER ........................................................................................................................................... 1 
1.2. THE RIP1TAG2 MOUSE MODEL OF MULTISTEP TUMORIGENESIS ....................................................... 2 
1.3. MECHANISMS CONTRIBUTING TO TUMOR PROGRESSION AND METASTASIS ...................................... 4 
1.3.1. Cell adhesion molecules in tumor progression and metastasis ................................................ 4 
1.3.2. Tumor lymphangiogenesis ....................................................................................................... 6 
1.4. NEURAL CELL ADHESION MOLECULE (NCAM) .............................................................................. 9 
1.4.1. NCAM structure, expression and function ............................................................................... 9 
1.4.2. More than just an adhesion molecule-NCAM’s role in signal transduction ...........................11 
1.4.3. The role of NCAM in tumor progression: Rip1Tag2;NCAM knock-out mice .........................13 
1.5. INTEGRINS .......................................................................................................................................18 
1.5.1. Function and composition of integrins....................................................................................18 
1.5.2. Integrin signaling ....................................................................................................................19 
1.5.3. The functions of integrin signaling .........................................................................................22 
1.5.4. Integrins in tumor progression................................................................................................22 
1.6. AIMS OF THE STUDY ........................................................................................................................24 
2. NCAM BINDS TO THE PDGFRβ AND POTENTIALLY REDUCES ITS ACTIVITY .............26 
2.1. INTRODUCTION ...............................................................................................................................26 
2.2. MATERIALS AND METHODS ............................................................................................................28 
2.2.1. Antibodies and reagents ..........................................................................................................28 
2.2.2. Tissue culture ..........................................................................................................................28 
2.2.3. Stable transfection of NIH 3T3 cells .......................................................................................28 
2.2.4. Cell stimulation, protein extraction and Western Blot ............................................................28 
2.2.5. Immunoprecipitation ...............................................................................................................29 
2.3. RESULTS .........................................................................................................................................30 
2.3.1. NCAM associates with all members of the FGFR family ........................................................30 
2.3.2. NCAM associates with PDGFRβ ............................................................................................31 
2.3.3. NCAM reduces tyrosine phosphorylation on the PDGFRβ ....................................................33 
2.3.4. Loss of NCAM enhances PDGF-BB induced activation of MAPK .........................................35 
2.4. DISCUSSION ....................................................................................................................................38 
3. NCAM ACTS AS A MOLECULAR SWITCH FOR FGFR SIGNALING ....................................41 
3.1. INTRODUCTION ...............................................................................................................................41 
3.2. EXPERIMENTAL PROCEDURES .........................................................................................................43 
Table of contents 
 II 
3.2.1. Cell lines and reagents ............................................................................................................43 
3.2.2. Stable transfection of L cells ...................................................................................................43 
3.2.3. Cell stimulation, protein extraction and Western Blot ............................................................43 
3.2.4. Immunoprecipitation ...............................................................................................................44 
3.2.5. Cell adhesion assays ...............................................................................................................44 
3.2.6. Cell proliferation ....................................................................................................................44 
3.3. RESULTS .........................................................................................................................................46 
3.3.1. NCAM-induced cell-matrix adhesion requires the binding of NCAM to FGFR. ....................46 
3.3.2. NCAM-induced cell-matrix adhesion is mediated by Erk1/2 activation .................................48 
3.3.3. NCAM and FGF activate distinct, FGFR-mediated signaling pathways ...............................50 
3.3.4. NCAM regulates the cellular response to FGF .......................................................................55 
3.4. DISCUSSION ....................................................................................................................................57 
4. Β1-INTEGRIN DELETION INDUCES TUMOR CELL DISSEMINATION AND REDUCTION 
OF TUMOR BURDEN IN THE RIP1TAG2 MODEL ............................................................................61 
4.1. INTRODUCTION ...............................................................................................................................61 
4.2. MATERIALS AND METHODS ............................................................................................................63 
4.2.1. Histopathological analysis ......................................................................................................63 
4.2.2. Mouse tissue processing ..........................................................................................................64 
4.2.3. Tissue culture ..........................................................................................................................64 
4.2.4. Cell adhesion ..........................................................................................................................64 
4.2.5. Cell proliferation ....................................................................................................................65 
4.2.6. FACS analysis of tumors .........................................................................................................65 
4.3. RESULTS .........................................................................................................................................66 
4.3.1. β1-integrin is required for islet cell sorting .............................................................................66 
4.3.2. Deletion of β1-integrin reduces tumor mass ...........................................................................67 
4.3.3. Loss of β1-integrin induces tumor cell dissemination into lymphatics ...................................70 
4.3.4. β1-integrin-deficient β tumor cells exhibit proliferation deficiencies .....................................72 
4.3.5. β1-integrin expression, but not NCAM is necessary for metastasis formation .......................75 
4.4. DISCUSSION ....................................................................................................................................77 
4.4.1. β1-integrin function is required for proper islet development .................................................77 
4.4.2. β1-integrin outside-in signaling but not NCAM mediated inside-out signaling is required for 
metastasis formation .............................................................................................................................77 
4.4.3. Loss of β1-integrin reduces tumor burden potentially by inducing senescence ......................78 
4.4.4. Loss of β1-integrin induces tumor cell cluster dissemination but not lymphangiogenesis ......79 
5. GENERAL DISCUSSION ..................................................................................................................81 
6. REFERENCES ....................................................................................................................................82 
7. CURRICULUM VITAE .....................................................................................................................93 
Table of contents 
 III






Neural Cell Adhesion Molecule (NCAM) is a member of the large family of Ca2+-
independent, immunoglobulin (Ig)-like cell adhesion molecules. So far, its function in homophilic 
and heterophilic interactions has been mainly studied in neuronal cells, where it is implicated in 
processes such as neurite outgrowth, axon guidance and pathfinding. Apart form its action as a 
cell adhesion molecule, NCAM contributes to these processes by acting as a modulator of 
fibroblast growth factor receptor (FGFR) signaling.  
NCAM is also expressed in a number of non-neuronal tissues and changes in NCAM 
expression levels have been correlated with increased malignancy in various tumors. In the 
Rip1Tag2 mouse model of multistage tumorigenesis, deletion of NCAM expression results in the 
induction of tissue disaggregation, increased lymphangiogenesis and the formation of metastases. 
Comparison of cell lines derived from NCAM-expressing and NCAM-deficient tumors showed 
that NCAM binds to FGFR and thereby activates it, triggering signaling cascades that eventually 
lead to the activation of β1-integrin, resulting in the promotion of cell-matrix adhesion. However, 
it has remained elusive how NCAM loss leads to the induction of lymphangiogenesis and whether 
the impaired cell matrix adhesion of NCAM-deficient cell lines accounted for the tissue 
disaggregation and metastasis formation observed in vivo.  
This study investigates NCAM function on several cellular levels. In in vitro co-
expression studies NCAM complex formation properties on the cell surface were investigated, 
showing that NCAM can bind to several growth factor receptors containing Ig domains in their 
extracellular parts. Studies focusing on the cytoplasmic events and molecular players downstream 
of the NCAM/FGFR complex formation, revealed a novel, inhibiting function of NCAM in 
modulating RTK signaling. Finally, in an in vivo approach, the role of β1-integrin, a target protein 
of NCAM signaling, in tumor progression was analyzed by interfering with β1-integrin 
expression in the Rip1Tag2 tumor model. These studies demonstrated that the induction of 
lymphangiogenesis in NCAM-deficient tumors was not due to the loss of β1-integrin function and 
therefore employed an alternative pathway. Yet, loss of β1-integrin induced tumor cell 
dissemination but not metastasis formation. Instead, a novel function of β1-integrin in tumor 
progression was identified. Upon deletion of β1-integrin, tumor size was decreased, potentially 
through the induction of senescence in β1-integrin-deficient cells. 
Taken together, this study has identified novel NCAM-binding proteins and provides 
insights into NCAM signaling on the molecular level as well as in an in vivo context. 







Das Neurale Zelladhäsionsmolekül (NCAM) ist ein Mitglied der grossen Familie der  aus 
Immunoglobulin (Ig) Domänen bestehenden, Ca2+-unabhängigen Zelladhäsionsmoleküle. Wie 
aus seinem Namen schliessen lässt, ist seine Funktion vorwiegend in neuronalen Geweben 
untersucht worden. Dort ist es in homophile und heterophile Interaktionen involviert und steuert 
Prozesse wie das Neuritenwachstum oder die Führung von Axonen. In diesen Prozessen spielt 
eine weitere Funktion von NCAM, nämlich die Bindung zu einem Wachstumsfaktor-Rezeptor 
(FGFR-1) und die Modulierung dessen Aktivität, eine essentielle Rolle. 
  NCAM ist auch in anderen, nicht-neuronalen Geweben exprimiert. Interessanterweise 
korreliert eine Veränderung des Expressionsmusters von NCAM in einigen Tumoren mit erhöhter 
Malignität. In einem transgenen Mausmodell für Tumorigenese von Insulin-produzierenden β 
Zellen führt die Deletion von NCAM zu erhöhter Lymphangiogenese, Tumor-Disaggregation und 
der Bildung von Metastasen. Der Vergleich von Zelllinien, die aus NCAM-exprimierenden bzw. 
NCAM-deletierten Tumoren gewonnen wurden, ergab dass NCAM auch in diesen Zellen mit 
einem Wachstumsfaktor-Rezeptor assoziiert ist (FGFR-4). Die Bindung führt zu der Aktivierung 
des Rezeptors, wodurch Signalkaskaden losgelöst werden, die in der Aktivierung von β1-Integrin, 
einem Matrix-bindenden Protein, resultieren. Zellen, die NCAM verloren haben, zeigen daher 
eine geringere Fähigkeit an extrazelluläre Matritzes zu binden. 
 In dieser Studie untersuchten wir die zellulären Funktionen von NCAM auf 
verschiedenen Ebenen. In in vitro Studien erforschten wir, ob NCAM mit zusätzlichen 
Wachstumsfaktor-Rezeptoren an der Zelloberfläche interagieren kann und fanden in der Tat 
mehrere Rezeptoren die an NCAM binden. Ausserdem untersuchten wir auch Vorgänge innerhalb 
der Zelle. In Experimenten, die auf die Identifizierung der einzelnen Moleküle in der 
Signalkaskade abzielten, fanden wir eine neue, den Rezeptor inhibierende Funktion von NCAM. 
 Schlussendlich untersuchten wir, ob die Deletion des Zielproteins der NCAM-induzierten 
Signalkaskade, β1-Integrin, ähnliche Auswirkungen auf die Tumorigenese hat wie die Deletion 
von NCAM selbst. Im speziellen waren wir daran interessiert, ob der Verlust dieser 
Signalkaskade zu erhöhter Lymphangiogenese führt und diese Signalkaskade somit einen 
Regulationsmechanimus für Lymphangiogenese darstellt. Weiters interessierte uns, ob der 
Verlust von β1-Integrin zu Tumorzell-Disaggregation und dies wiederum zur Bildung von 
Metastasen führt. Wir fanden heraus, dass die Regulierung von Lymphangiogenese unabhängig 
von der NCAM induzierten Signalkaskade zu β1-Integrin ist. Deletion von β1-Integrin resultiert 
jedoch in der Loslösung von Tumorzellgruppen in lymphatische Gefässe, nicht aber in der 
Bildung von Metastasen. Interessanterweise sind β1-Integrin-negative Tumoren kleiner, 
vermutlich, weil der Verlust von β1-Integrin zur Zell-Seneszenz führt. Hiermit haben wir eine bis 
dato unbekannte Funktion von β1-Integrin identifiziert. 
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Cancer, from the Greek word carcinos (crab, crayfish) was already described and studied 
by the ancient Greek physician Hippocrates around 400 years BC. Today, cancer is one of the 
leading causes of death in the developed world. Cancer arises when cells acquire fundamental 
changes in their genome, leading to disturbances in their behavior within the context of a multi-
cellular organism. To understand and eventually treat cancer, experimental and clinical research 
from the last decades has accumulated a huge and complex amount of knowledge, focusing on 
oncogenes with dominant gain of function mutations and tumor suppressor genes with recessive 
loss of function mutations as well as other molecular players of cancer development. 
  An increasing body of evidence suggests that tumorigenesis is a multistep process, a 
succession of genetic changes, leading to the progressive conversion of normal cells into cancer 
cells. Despite the fact that the actual molecules or changes important in tumor initiation and 
progression might differ among the hundreds of cancer types, it has becomes more apparent that 
most, perhaps all solid cancers have acquired and share a small number of common, principle 
properties. It has been suggested that six essential alterations in cell physiology together instruct 
malignant growth (Hanahan and Weinberg, 2000)  
These alterations include, in the initial tumor stages, the insensitivity of cells to anti-
proliferative signals, evasion of apoptosis and acquired self-sufficiency in growth signals. For 
further progression from benign to malignant cancers, the genetic changes lead to the gain of 
limitless replicative potential, sustained angiogenesis and finally the capability to invade tissues 






Figure 1: The Hallmarks of Cancer 
Common functional traits acquired by cells during the 
formation of tumors and the progression to malignant 
cancers. Adapted from (Hanahan and Weinberg, 2000) 
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1.2. The Rip1Tag2 mouse model of multistep tumorigenesis 
 
In order to study genetic alterations and the molecular mechanisms of tumorigenesis in 
vivo, various mouse models of tumorigenesis have proven to be invaluable tools. Several 
approaches to induce carcinogenesis have been developed over the last thirty to forty years. For 
example, chemical mutagens such as 7,12-dimethylbenzanthracene (DMBA) or ethyl-nitrosourea 
(ENU) have been used to induce skin cancers (Quintanilla et al., 1986). However, this method is 
currently used preferentially in combination with genetically modified mouse lines (Balmain, 
2002). In another approach, tumor cell suspensions are orthotopically, subcutaneously or 
intravenously injected into immune-deficient mice, allowing investigators to assay potential 
effects of different treatments on tumors as well as to monitor capabilities of cells to metastasize 
to specific organs (Kubota, 1994).  
However, the use of these two model systems is limiting in respect to the investigation of 
type and localization of primary tumor formation, and because of the absence of an intact immune 
system. This limitation can be overcome by the use of genetically modified mice, in which 
oncogenes are introduced into the mouse germ line or gene functions are ablated by homologous 
recombination.  Further improvement can be gained through the development of techniques to 
induce or delete gene function in specific tissues and/or at certain time points (tissue specific, 
inducible transgenic mice or tissue specific, conditional knock out mice). These models therefore 
allow more controlled reproduction of sporadic tumor onset and progression and have been used 
for many proof-of-concept studies, demonstrating the causal function of a particular gene in 
tumor development. 
The introduction of highly oncogenic viral proteins, such as for example the large T 
antigen (Tag) of simian virus 40 (SV40) into the mouse genome is frequently used to generate 
tumor-bearing transgenic mice. Tag expression disrupts cell cycle control by binding to and 
inactivating the tumor suppressor gene products p53 and pRb, leading to cell transformation and 
tumor development.  
The Rip1Tag2 mouse model was established about twenty years ago (Hanahan, 1985). In 
these mice, Tag expression is targeted specifically to the pancreatic islets of Langerhans using the 
β cell specific Rat insulin promoter  (Rip). In the mouse, around 400 islets of Langerhans 
(endocrine tissue of the pancreas) can be found embedded in the exocrine pancreas. Each islet is 
composed of a set of secretory cells, namely glucagon-producing α cells, somatostatin-producing 
γ cells, pancreatic polypeptide (PP) cells and, most abundant in islets, the insulin-producing β 
cells. In the Rip1Tag2 transgenic mice, T antigen expression starts at embryonic day 8.5, but it is 
not until the age of 4 weeks that hyperplastic islets begin to appear. Even though all islets express 
Tag, only 50% develop into hyperplastic lesions at the age of 10 weeks. The onset of an 
angiogenic switch in a subset of hyperplastic islets triggers the formation of new blood vessels, 
resulting in the progression to angiogenic islets at 6 weeks and solid tumors at 9 to 10 weeks of 
age. At 12 to 14 weeks, 2%-4% of all islets have developed into well-encapsulated, benign 
tumors (adenomas) and only 0.5% of all islets advance into de-differentiated, invasive carcinomas 
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(Figure 2). Importantly, these mice never develop metastases, probably because they succumb to 
hypoglycemia around the age of 14 weeks. Thus, the Rip1Tag2 model is a model for multistage 
tumorigenesis in which tumors of all different stages can be reproducibly found and investigated, 
making it a very powerful tool to study distinct molecular events that may influence tumor 
growth and progression as well as tumor angiogenesis, lymphangiogenesis and metastasis.  
 
Figure 2: Multistep β cell carcinogenesis in Rip1Tag2 transgenic mice 
As indicated, islets (black dots) sequentially progress into hyperplastic islets (large brown ellipses), 
angiogenic islets (red ellipses), benign adenoma (large red shapes), and malignant carcinoma (blue 
shape). Percentages indicate the subset of initial islets that have developed into a specific tumor grade at 
12-14 weeks of age. The exocrine pancreatic tissue is drawn in light brown. E8.5, embryonic day 8.5 
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1.3. Mechanisms contributing to tumor progression and metastasis 
 
Most cancer deaths result from the formation of metastases at distant sites rather than 
from the primary tumors themselves. Just like primary tumor initiation, it is now believed that 
tumor progression and metastasis are processes that involve several rate-limiting steps. 
Importantly, these processes do not only involve changes in the tumor cells per se, but also 
require additional concerted, “pro-metastatic” contributions from the tumor microenvironment, 
(Kopfstein and Christofori, 2006).  
After the initial transformation and growth of cells, and when tumors exceed a mass of  
1 mm, tumors have to induce neo-vascularisation or angiogenesis in order to survive and further 
proceed. The synthesis and secretion of several pro-angiogenic factors by tumor and host cells 
and the absence of anti-angiogenic factors play a key role in establishing a capillary network from 
the surrounding host tissues. The “angiogenic switch” allows not only the tumors to have access 
to required nutrients but also eventually provides a route for haematogenic spread of cancer cells 
(Fidler, 2002; Ahmad and Hart, 1997). Blood vessel endothelial cells (BVECs) also secrete 
growth factors (such as PDGFs, EGFs and FGFs) that stimulate tumor cell growth and facilitate 
tumor lymphangiogenesis (Cao, 2005). 
In order to disseminate from the primary tumor, polarized epithelial cells have to convert 
into motile cells, gaining a fibroblastoid, migratory and invasive phenotype. Cell adhesion 
molecules have been shown to be important players in this process (Cavallaro and Christofori, 
2004) and will be discussed in more detail in the next section and in Chapter 1.5. Next, malignant 
tumor cells have to further invade the local ECM, intravasate into tumor-associated lymphatics or 
vasculatures, avoid immunological attacks as well as survive and proliferate in the circulation and 
the secondary organ tissues after extravasation. However, in these processes, tumor cells get 
supported by their surrounding environment. Among others, tumor associated macrophages 
(TAMs) and carcinoma associated fibroblasts secrete several factors, as for instance growth 
factors, matrix metalloproteinases (MMPs) or cytokines, supporting remodeling of the ECM, cell 
survival, invasion and immune tolerance (reviewed in Bogenrieder and Herlyn, 2003; Fidler, 
2002; Ahmad and Hart, 1997, Kopfstein and Christofori, 2006). 
 
 
1.3.1. Cell adhesion molecules in tumor progression and metastasis 
 
The “prototype” and probably best-studied cell adhesion molecule (CAM) is E-cadherin, 
a member of the classical cadherin family of CAMs. Classical cadherins are single-span 
transmembrane domain glycoproteins, localized in adherens junctions and desmosomes. They 
mediate cell-cell adhesion by homophilic protein-protein interaction at the cell surface in a Ca2+-
dependent way.  
At their cytoplasmic tails, Cadherins interact with various proteins, termed catenins, to 
assemble a cytoplasmic cell adhesion complex (CCC). β-catenin and γ-catenin (also named 
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plakoglobin) bind to the same conserved site at the C-terminus of E-cadherin in a mutually 
exclusive way (Ozawa et al., 1989; Nathke et al., 1994), whereas p120ctn interacts with multiple 
sites on the cytoplasmic tail of E-cadherin, including the juxtamembrane region.  Direct binding 
of β-catenin and γ-catenin to α-catenin links the CCC to the actin cytoskeleton.  Formation of the 
CCC is dependent on cell-cell adhesion, and conversely, disturbance of the CCC compromises 
cadherin-mediated cell-cell adhesion.  
 E-cadherin is expressed in epithelial cells and is a key player in the maintenance of cell 
polarity and epithelial organization (Gumbiner, 2005).  In many tumors of epithelial origin, loss 
of E-cadherin-mediated cell-cell adhesion was observed to coincide with progression towards 
malignancy, and reduced E-cadherin levels were correlated with poor prognosis, suggesting a 
critical role of this CAM in tumor progression. In fact, forced expression of E-cadherin in 
cultured tumor cells lead to the re-establishment of a functional E-cadherin-catenin complex and 
resulted in the reversion from an invasive, mesenchymal phenotype to a benign, epithelial 
phenotype in vitro (Vleminckx et al., 1991).  
Using the above described Rip1Tag2 tumor model, our group demonstrated previously 
that loss of E-cadherin mediated cell-cell adhesion is causally involved in the progression from 
adenoma to carcinoma in vivo and is one rate limiting step in the conversion from adenoma to 
carcinoma as well as the subsequent formation of metastases. Intercrossing Rip1Tag2 mice with 
transgenic mice that maintain E-cadherin expression in the β cells of pancreatic islets lead to 
arrest of tumor progression at the adenoma stage. In contrast, expression of a dominant-negative 
form of E-cadherin in the same tumor model induced early invasion and metastasis (Perl et al., 
1998).  
The mechanisms by which E-cadherin down-regulation in tumors leads to a more 
invasive phenotype might be similar to the mechanisms of a phenomenon that normally occurs 
during embryonic development, inflammation, tissue remodeling and wound healing, namely the 
epithelial to mesenchymal transition (EMT; Grunert et al., 2003).  During EMT, cells down-
regulate epithelial markers such as E-cadherin and up-regulate the expression of various 
mesenchymal markers, like N-Cadherin and vimentin (Thiery, 2002). Recently, our lab revealed 
that E-cadherin down-regulation also induced the expression of the neuronal cell adhesion 
molecule, NCAM (Lehembre et al., submitted). E-cadherin loss leads to the disassembly of 
adhesion junctions between neighboring cells, reduced cell polarity and increased migratory and 
invasive-growth properties. Several potential signaling pathways are thought to have an active 
part in this process and only two of them are discussed hereafter (Cavallaro and Christofori, 
2004).  
Components of the CCC, namely β-catenin and γ-catenin do not only play crucial roles in 
the assembly of the complex but also have important functions in the canonical WNT-signaling 
pathway (Bienz and Clevers, 2000; Polakis, 2000). If they are not engaged in the CCC, free 
cytosolic β-catenin and γ-catenin are phosphorylated by glycogen synthase 3β (GSK3β) in a 
complex also involving the proteins adenomatous polyposis coli (APC) and axin. Following 
phosphorylation, β-catenin and γ-catenin are degraded. If the tumor suppressor APC is non-
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functional (as observed in many colon cancer cells), or GSK3β activity is blocked by the 
activated WNT-signaling pathway, β-catenin is not degraded, therefore accumulates in the 
cytoplasm and further translocates to the nucleus, where it binds to members of the TCF/LEF1 
family of transcription factors. Thereby it modulates the expression of several target genes that 
are implicated in cell proliferation and progression. 
Other signals induced through the loss of E-cadherin might affect the actin cytoskeleton 
and thereby modulate the migratory properties of cells. The family of RHO GTPases, including 
RhoA, Rac1 and Cdc42 are implicated in the formation of actin stress fibers, lamellipodia and 
filopodia (see also section 1.5.3.). E-cadherin, when engaged in cell-cell adhesion, can suppress 
RhoA activity. Furthermore, free (not engaged in the CCC) cytosolic p120ctn is able to recruit and 
activate Rac1 and Cdc42, thereby promoting cell migration (Cavallaro and Christofori, 2004). 
In most cases, E-cadherin is down-regulated on the transcriptional level: the 
transcriptional repressors Snail (Batlle et al., 2000), Slug (Hajra et al., 2002) and Sip1 (Comijn et 
al., 2001) as well as E12/E47 (Perez-Moreno et al., 2001) bind to the promoter of the E-cadherin 
gene and actively repress its expression (see also section 1.5.4.). Furthermore, a negative 
correlation between E-cadherin levels and the expression of the transcription factor Twist have 
been reported (Yang et al., 2004). It is not clear, though, if Twist binds directly to the E-cadherin 
promoter or modulates E-cadherin levels in an indirect way. In many cancers, such as thyroid 
carcinomas, further down-regulation is achieved epigenetically by the subsequent silencing of the 
E-cadherin promoter through hypermethylation (Di Croce and Pelicci, 2003). Moreover, 
mutations in the E-cadherin gene that lead to the expression of a non-functional protein have been 
reported in patients with diffuse gastric cancer, lobular breast cancer, thyroid, bladder and 
gynecological cancers (Strathdee, 2002).  
Finally, tyrosine phosphorylation of the CCC has been implicated in the regulation of 
cadherin function. RTKs such as epidermal growth factor receptor (EGFR), hepatocyte growth 
factor receptor (c-Met) and fibroblast growth factor receptor (FGFR), as well as Src 
phosphorylate E-cadherin, β- and γ-catenin and p120ctn , resulting in the disassembly of the CCC 
(Behrens et al., 1993). One mechanism by which RTKs can disrupt the CCC is by targeting E-
cadherin for degradation: recently, a E3 ligase named Hakai has been identified. Hakai 
specifically binds and ubiquitylates tyrosine-phosphorylated E-cadherin, resulting in endocytosis 
and proteasomal degradation of E-cadherin (Fujita et al., 2002). Interestingly, this process seems 
to be, at least under certain circumstances, dependent on β1-integrin (see section 1.5.4.). 
 
 
1.3.2. Tumor lymphangiogenesis 
 
Angiogenesis, or formation of new blood vessels from pre-existing ones, is essential for 
normal development and wound healing. Abnormal regulation of angiogenesis has been 
implicated in the pathogenesis of several disorders, including cancer.  Newly formed tumor-
associated blood vessels do not only support tumor progression by supplying growing tumors 
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with oxygen but, also contribute to the metastatic process by providing a route for haematogenic 
metastasis of tumor cells. The molecular mechanisms underlying tumor angiogenesis have been 
studied to a great extent, leading to the discovery of potential targets for drug development. For 
example, the vascular endothelial growth factor A (VEGF-A) has been identified in playing a key 
role in angiogenesis. Early clinical experience with the anti-VEGF-A monoclonal antibody 
Avastin (Genentech) support the hypothesis that its inhibition may represent a novel approach for 
cancer treatment (Ferrara, 2002; Carmeliet and Jain, 2000). 
Attention to tumor-lymphangiogenesis, the formation of new tumor-associated lymphatic 
vessels was drawn to researchers only recently. The identification of lymphatic specific markers 
such as the homeobox transcription factor Prox-1 (Wigle and Oliver, 1999) or the lymphatic 
vessel endothelial hyaluronan receptor-1 (LYVE-1) (Banerji et al., 1999), as well as the 
development of new molecular tools advanced research in this area (Pepper and Skobe, 2003).   
The physiological function of lymphatic vascular networks in the body is to drain 
interstitial fluid from tissues and to return it to the blood. Furthermore, lymphatic vessels are also 
an essential part of the body’s immune defense by directing leukocytes and antigens from tissues 
to lymph nodes. Structurally, lymphatic vessels are distinct from blood vessels: lymphatic 
capillaries are thin-walled, relatively large capillaries composed of a single layer of overlapping 
endothelial cells. They are not covered by smooth muscle cells and have little or no basement 
membrane. Lymphatic capillaries are attached to tissue stroma via elastic anchoring filaments. 
With increasing tissue pressure, these filaments pull on the endothelial cells, opening the gaps 
between the overlapping cells and thereby allowing fluid influx (Alitalo et al., 2005).  
Lymphatic vessels could contribute to tumor growth in various ways. They provide a 
route and thereby facilitate the metastatic spread of tumor cells, and indeed, lymphogenic 
metastasis occurs at least as frequently as haematogenous metastasis (Cao, 2005). Because of 
their structural features, it might be even easier for tumor cells to invade into lymphatic vessels 
than into blood vessels. Since lymphatic endothelial cells (LECs), similar to blood vessel 
endothelial cells (BVECs) express matrix metalloproteinases (MMPs) and urokinase plasminogen 
(uPA), they might directly or indirectly potentiate the invasiveness of tumors. Lastly, a rather 
controversial hypothesis suggests that lymphatic growth into tumors is induced in order to reduce 
the increased interstitial fluid pressure of a given tumor. However, it is not clear yet if lymphatic 
vessels within tumors are fully functional (Cao, 2005). 
Several molecular players important for lymphatic development and lymphangiogenesis 
have been identified and are described in detail elsewhere (Alitalo et al., 2005). In general, the 
majority of lymphangiogenic signals are mediated via the vascular endothelial growth factor 
receptor-3 (VEGFR-3; Kaipainen et al., 1995) a member of the (Ig) domain containing receptor 
tyrosine kinase (RTK) family. VEGFR-3 is primarily expressed on lymphatic endothelial cells 
and required for the formation of lymphatic vasculature in both, embryonic development and in 
the adult (Karkkainen and Petrova, 2000). High affinity ligands for VEGFR-3 are vascular 
endothelial growth factor-C (VEGF-C; Joukov et al., 1996) and VEGF-D (Achen et al., 1998). 
Both factors induce, upon binding, receptor activation.  The subsequent signaling events result in 
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lymphangiogenesis as shown in transgenic models for both factors (Mandriota et al., 2001; 
Veikkola et al., 2001).  
Importantly, when VEGF-C and VEGF-D transgenic mice were crossed into the 
Rip1Tag2 tumor mouse model, both factors induced tumor-associated lymphangiogenesis and the 
formation of metastases (Mandriota et al., 2001; Kopfstein et al., submitted). VEGF-C expression 
has been reported to be induced in tumor cells and tumor-associated macrophages, but the 
pathways leading to VEGF-C and VEGF-D de novo expression in tumors remain elusive. 
Interestingly, ablation of the neural cell adhesion molecule (NCAM) in Rip1Tag2 mice results in 
VEGF-C and VEGF-D expression, and in the induction of lymphangiogenesis and metastasis 
formation (Crnic et al., 2004) see also section 1.4.3.   
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1.4. Neural Cell Adhesion Molecule (NCAM) 
 
1.4.1. NCAM structure, expression and function 
 
Neural Cell Adhesion Molecule (NCAM, CD56) was the first CAM to be characterized 
and therefore has been studied extensively (Brackenbury et al., 1977; Cunningham et al., 1987; 
Crossin and Krushel, 2000). NCAM is encoded by a single gene, located on chromosome 11 in 
humans (Nguyen et al., 1986; Walsh et al., 1986) and on chromosome 9 in mice (D'Eustachio et 
al., 1985). Alternative splicing gives rise to three major isoforms, named after their relative 
molecular weight (Mr) (Owens et al., 1987). NCAM140 and NCAM180 are single spanning 
transmembrane proteins and differ in the length of their cytoplasmic domains, whereas 
NCAM120 is attached to the cell membrane via a glycophosphatidyl inositol (GPI-) anchor 
(Figure 3). In addition to the three main isoforms, the molecule also exists in a secreted form 
(soluble NCAM), produced by the expression of the so called SEC-exon that contains a stop-
codon, giving rise to a truncated form of the extracellular part of NCAM with a Mr of around 
115kD (Bock et al., 1987; Gower et al., 1988). Soluble NCAM also exist in a shedded form, 
resulting from the enzymatic removal of NCAM120 from the membrane or by proteolytic 
cleavage of any of the three major isoforms (He et al., 1986). 
NCAM belongs to the immunoglobulin-like superfamily of adhesion molecules (Ig-
CAMs): the extracellular, N-terminal part of all NCAM isoforms consists of five Ig-like domains 
(Ig1-5) followed by two fibronectin type III (F3) modules proximal to the membrane 
(Cunningham, 1995). Variability in the extracellular part is obtained by the optional insertion of 
additional exons, as for example the variable alternative spliced exon (VASE) in the Ig4 domain 
that is expressed at high levels in the adult central nervous system, serving to down-regulate axon 
growth (Doherty et al., 1992; Figure 3)  
Further variation of NCAM expression, and therefore function, is achieved by 
posttranslational modifications of the protein. Attachment of the negatively charged sugar 
polysialic acid to the fifth Ig domain induces a shift in the adhesive properties of NCAM 
(Fujimoto et al., 2001), changing it form a pro-adhesive to a pro-migratory molecule, facilitating 
axon path-finding and plastic changes in the embryonic and adult nervous system (Hoffman et al., 
1982; Angata and Fukuda, 2003; Bruses and Rutishauser, 2001). Additional post-translational 
modifications are found on the C-terminal, intracellular domains of NCAM140 and NCAM180. 
Both cytoplasmic domains can be palmitoylated, which determines NCAMs association with lipid 
rafts in the membrane and thereby its signaling properties (Brackenbury et al., 1987; Little et al., 
1998). 
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Figure 3: The three major NCAM isoforms 
NCAM is expressed as three major isoforms. Two of them are transmembrane forms with either long 
(NCAM180) or short (NCAM140) cytoplasmic domains, while the third isoform (NCAM120), lacking a 
cytoplasmic domain, is anchored to the plasma membrane by a GPI-linkage. All three isoforms have five 
Ig-like domains and two Fibronectin type III (FN3) domains in the extracellular region. NCAM180 has an 
additional 261 amino acid insert at the cytoplasmic tail. The alternatively spliced VASE exon in the Ig4 
domain (see text) is also indicated. All three isoforms can be post-translationally modified by the addition 
of polysialic acid (PSA) to the Ig5 domain. 
 
NCAM is a Ca2+-independent adhesion molecule and engaged in both, homophilic and 
heterophilic interactions. This, together with the above described transcriptional and post-
translational modifications of the NCAM protein, results in a variety of adhesive properties and 
functions. During development, NCAM140 and NCAM180 are transiently expressed in the 
nervous system as well as in several other tissues (Crossin et al., 1985). Expression of these 
isoforms, also called “embryonic” isoforms, plays a pivotal role in developmental events such as 
neuronal cell migration, differentiation and proliferation (Walsh and Doherty, 1997; Kiss and 
Muller, 2001). In the adult, however, NCAM120 is the major isoform to be expressed in the 
nervous system (Gower et al., 1988), in skeletal muscle cells (Dickson et al., 1987) as well as 
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1.4.2. More than just an adhesion molecule-NCAM’s role in signal transduction 
 
The nature of NCAM homophilic interaction and its role in cell-cell adhesion has been 
studied in great detail (reviewed in Walmod et al., 2004). However, NCAM is also involved in 
heterophilic interaction with several proteins, both via the extracellular as well as the intracellular 
regions of the protein.  In neuronal PC-12 cells, NCAM function results in the induction of long 
neuronal processes called neurites (Doherty et al., 1991). Neurite outgrowth therefore has been 
repeatedly used as a read-out assay to study NCAMs intracellular signaling, mediated by the 
induction of downstream signal transduction pathways through the direct or indirect interaction of 
NCAM with heterophilic ligands.  
Already 10 years ago, it has been suggested that NCAMs induction of neurite outgrowth 
involves an interaction with the fibroblast growth factor receptor (FGFR; Doherty and Walsh, 
1996; Kiselyov et al., 2003).  Several studies using dominant negative versions of FGFR (Ronn et 
al., 2000; Saffell et al., 1997) as well as specific inhibitors of enzymes (Kolkova et al., 2000) and 
second messenger molecules (Williams et al., 1994a) lead to the following model (depicted in 
Figure 4): Upon binding to the FGFR, NCAM stimulates FGFR dimerisation and activation by 
auto-phosphorylation. Subsequently, several proteins dock to the receptor’s cytoplasmic tail, one 
of them being the enzyme phospholipase Cγ (PLCγ), which, upon recruitment, becomes activated. 
PLCγ cleaves its substrate phosphatidylinositol 4,5-bisphosphate (PIP2), generating the second 
messenger molecules inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 induces the 
release of Ca2+ by binding to intracellular Ca2+-channels, whereas DAG remains at the membrane 
and can either activate protein kinase C (PKC) or be converted (by DAG lipase) into 2-
arachidonylglycerol (2-AG) and arachidonic acid (AA), inducing various downstream signaling 
events (Walmod et al., 2004).  
Since treatment of cells with AA has been shown to induce Ca2+-influx and neurite 
outgrowth, AA was thought to be the signal-transmitting product downstream of DAG lipase 
(Williams et al., 1994b). However, it has been recently shown that FGF-induced neurite 
outgrowth is mediated by 2-AG (Williams et al., 2003). 2-AG can activate the cannabinoid 
receptors CB1 and CB2 that subsequently, among other signaling events, induce calcium influx. 
Addition of AA to cells might lead to increased levels of 2-AG and therefore indirectly lead to 
stimulation of 2-AG signaling. However, the importance of this process in NCAM-mediated 
neurite outgrowth remains to be determined (Williams et al., 2003).  
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Figure 4: NCAM-mediated signal transduction pathways 
NCAM induces different signal transduction pathways resulting in neurite outgrowth (see text). The 
structure of physical interaction between two fibronectin type III domains of NCAM (see also Figure 3) and 
Ig domains 2 and 3 of FGFR has been recently shown (Kiselyov et al., 2003). Dashed lines represent 
putative interactions. This is a simplified depiction, modified from (Povlsen et al., 2003). 
 
In addition to signaling through FGFR, NCAM has been shown to signal and induce 
neurite outgrowth via non-receptor tyrosine kinases: clustering of the NCAM140 isoform in the 
neural plasma membrane stimulates the activating phosphorylation of mitogen-activated protein 
kinases (MAPKs) and the transcription factor cyclic AMP response-element binding protein 
(CREB). NCAM clustering transiently induces dual phosphorylation (activation) of the MAPKs 
ERK1 and ERK2 (extracellular signal-regulated kinases) by a pathway regulated by the focal 
adhesion kinase FAK and p59Fyn, both of which have been shown to associate with NCAM140 
(Beggs et al., 1997; Schmid et al., 1999; Figure 3). Furthermore, recent reports show that NCAM 
can interact with glial cell line derived neurotrophic factor (GDNF) and the GDNF family 
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receptor GFRα. The interactions induce neurite outgrowth in an FGFR-independent manner, 
involving signaling mediated via p59Fyn (Paratcha et al., 2003). However, it is not yet clear if the 
above mentioned signaling events involving p59Fyn, FAK and MAPK also require GDNF and 
GFRα.  Whether NCAM signals through FGFR/PLCγ or p59Fyn/FAK depends on its localization 
on the membrane: only lipid-raft associated NCAM can induce p59Fyn/FAK signaling, in contrast, 
FGFR signaling is induced by a non-raft fraction of NCAM. Still, both pathways are required for 
NCAM induced neurite outgrowth (Niethammer et al., 2002). Interestingly, our lab has shown 
that depletion of E-cadherin leads to increased expression of NCAM. Upon upregulation, NCAM 
molecules cluster and mediate homophilic binding, thereby modulating cell-cell contacts. 
Furthermore, NCAM localizes to lipid rafts and switches from a FGFR/PLCγ- to a p59Fyn-
containing complex leading to an increased number of focal contacts (Lehembre et al., submitted) 
A recent study, moreover, revealed that NCAM is linked to the cytoskeleton via the 
linker protein spectrin. Spectrin seems to be the bridge between NCAM and PKCβII. Whereas 
NCAM140 and NCAM180 associate with spectrin and PKCβII independent of lipid raft integrity, 
NCAM120’s association to these proteins is only found in a raft-dependent manner. However, 
FGFR-dependent formation of this complex is necessary for the induction of neurite outgrowth, 
indicating that the physical link of NCAM to the cytoskeleton is important for its signaling 
properties (Leshchyns'ka et al., 2003). 
 
 
1.4.3. The role of NCAM in tumor progression: Rip1Tag2;NCAM knock-out mice 
 
As already mentioned, NCAM is also expressed in non-neuronal tissues such as skeletal 
muscle cells (Dickson et al., 1987) as well as some neuroendocrine tissues (Rouiller et al., 1990; 
Cirulli et al., 1994; Langley et al., 1989). Interestingly, in many tumors, such as Wilm’s tumor 
(the most common kidney cancer affecting children), colon carcinoma, Ewing sarcoma 
(Peripheral Primitive Neuroectodermal Tumors (PNET) of bone), neuroblastoma, small cell lung 
cancer and multiple myeloma, NCAM expression changes from the adult, NCAM120 isoform in 
normal tissue to the embryonic, NCAM140 and NCAM180 isoforms in tumors (Johnson, 1991; 
Kaiser et al., 1996; Lipinski et al., 1987; Moolenaar et al., 1992; Roth et al., 1988). 
Furthermore, cancer progression correlates with up-regulation of NCAM in 
neuroblastoma and certain neuroendocrine tumors, and up-regulation of NCAM often coincides 
with extensive polysialylation (Komminoth et al., 1991; Angata and Fukuda, 2003; Lantuejoul et 
al., 1998; Lantuejoul et al., 2000; Gluer et al., 1998). In contrast, reduced or lost expression of 
NCAM in human astrocytoma, colorectal and pancreatic cancer has been correlated with 
increased tumor malignancy (Fogar et al., 1997; Sasaki et al., 1998; Huerta et al., 2001).  These 
findings prompted our group to investigate NCAMs function during tumor progression by 
ablation of NCAM expression in Rip1Tag2 tumorigenesis.  
Even though NCAM plays many important roles during development, NCAM knock-out 
mice (NCAM-/- mice) carrying a deletion in one or both alleles are born normally, are viable, 
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fertile and appear healthy. Adult mutants, however, show reduced brain weight and olfactory bulb 
size, deficits in spatial learning, altered exploratory behavior, increased intermale aggression and 
increased anxiety-like behavior (Stork et al., 1997; Ono et al., 1994; Tomasiewicz et al., 1993; 
Cremer et al., 1994; Stork et al., 1999). Moreover, in pancreatic islets of NCAM-deficient mice 
the normal localization of glucagon-producing α cells in the periphery of pancreatic islets is lost, 
resulting in a more randomized cell distribution (Esni et al., 1999). Notably, the islet-
developmental phenotype is the same in NCAM+/- as well as in NCAM-/- mice, suggesting that 
gene dosage is important for NCAM function in this tissue (Esni et al., 1999). 
During Rip1Tag2 tumorigenesis, NCAM expression changes from the adult, NCAM120 
isoform to the embryonic NCAM140 and NCAM180 isoforms (Perl et al., 1999). When 
intercrossed with NCAM-/- mice, the resulting RipTag2;NCAM-/- mice (RT2;NC-/- mice 
hereafter) do not show altered tumor progression from adenoma to carcinoma. However, in 50% 
of NCAM-deficient tumor mice, formation of metastases to the regional lymph nodes as well as 
distant organs is observed (Perl et al., 1999). Importantly, formation of metastases has not been 
found in hundreds of Rip1Tag2 mice analyzed. The metastatic phenotype of RT2;NC-/- mice is 
indistinguishable from that of RT2;NC+/- mice, which is in accordance with the above mentioned 
haploinsufficiency of the NCAM gene in NCAM+/- mice (Esni et al., 1999).  
Immunohistochemical examination revealed that NCAM-deficient Rip1Tag2 tumors 
exhibit up-regulated expression of the lymphangiogenic factors VEGF-C and -D and, with it, 
increased lymphangiogenesis (Figure 5). Repression of VEGF-C and -D function by adenoviral 
expression of a soluble form of their cognate receptor, VEGF receptor-3, results in reduced tumor 
lymphangiogenesis and lymph node metastasis (Crnic et al., 2004), indicating that loss of NCAM 
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Figure 5: Lymphangiogenesis is induced in RT2;NCAM-/- and RT2;NCAM+/-  mice 
Immunohistochemical staining of PFA-fixed pancreatic sections.  Whereas RT2;NC+/+ tumors are rarely 
associated with lymphatic vessels (panel A), NCAM-deficient tumors (panel B) show ongoing 
lymphangiogenesis, often being fully surrounded by structures positive for the lymphatic endothelial 
marker LYVE-1 (in brown, highlighted by arrowheads). T, tumor; E, exocrine pancreas; 
 
 Additionally to the increased lymphangiogenic phenotype, RT2;NC-/- tumors show 
striking alterations in tumor architecture, notably dramatic tissue disaggregation and the 
appearance of large hemorrhagic cavities. Clusters of tumor cells are frequently found floating in 
these lacunae (Cavallaro et al., 2001; Figure 6). Detailed analysis of cell lines derived from RT2 
control tumors (βT2 cells) and RT2;NC-/- tumors (βTN2 cells) revealed that cell-matrix but not 
cell-cell adhesion is impaired in NCAM deficient tumor cells, as assayed by their capability to 
adhere to the  ECM component Collagen IV. Moreover, βT2 cells show the formation of neurites, 
which are absent in βTN2 cells.  
 
 
Figure 6: Tissue disaggregation 
in RT2;NCAM-/- tumors 
H&E staining of RT2;NCAM+/+ 
(A) and RT2;NCAM-/- (B) tumors. 
In the absence of NCAM, tumors 
seem to fall apart, showing tissue 
disaggregation and the 
appearance of hemorrhagic 
lacunae filled with disseminated 
tumor cell clusters (indicated by 
arrows). 
 
These observations suggested that NCAM is able to modulate integrin mediated matrix 
adhesion, and, similar to the findings in neuronal cells, might be involved in the regulation of 
signaling processes in β cells. Extensive biochemical analysis indeed identified the signaling 
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pathway(s) linking NCAM to β1-integrin activation in vitro. In βT2 cells, NCAM associates with 
and activates a member of the fibroblast growth factor receptor (FGFR) family, FGFR-4. 
Interestingly, N-cadherin but not β1-integrin is also found in the NCAM/FGFR-4 complex.  
Activation of FGFR-4 results in the formation of a classical signaling complex, including 
phospholipase C gamma (PLC-γ), the adaptor protein FRS2, pp60 (c-src), cortactin and growth-
associated protein-43 (GAP-43). Dominant-negative FGFR-4, inhibitors of FGFR signaling and 
anti-β1-integrin antibodies repress matrix adhesion induced by NCAM. FGF ligands can replace 
NCAM in promoting matrix adhesion but not neurite outgrowth (Cavallaro et al., 2001). Taken 
together, the results indicate that NCAM stimulates β1-integrin-mediated cell-matrix adhesion by 
















Figure 7: Model of NCAM mediated 
signal transduction in β cells 
Upon associating with NCAM and N-
cadherin, FGFR-4 is activated and 
recruits a classical FGFR-signaling 
complex (see text for description). The 
molecular links between NCAM and 
integrin activation remain to be 
elucidated and are indicated by dashed 
arrows. Adapted from (Cavallaro and 
Christofori, 2004). 
 
In summary, the above described findings for the functional contribution of NCAM to 
Rip1Tag2 β cell tumorigenesis lead to the rather provocative suggestion of an alternative 
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metastatic pathway: Loss of NCAM leads to tissue disaggregation and the formation of lacunae 
potentially by the loss of substrate adhesion of β cells. However, the cells comprising the 
disseminated tumor clusters are still able to adhere to each other and exhibit a rather benign 
phenotype. They might be simply washed out by the blood or lymphatic circulation. 
Subsequently, they might be entrapped in the local lymph nodes where they grow out to form 
metastases.  
In contrast to the current view on metastatic processes, this model of “passive 
metastasation” implies that, in order to metastasize, tumor cells do not necessarily have to acquire 
an migratory, invasive phenotype, for example by losing E-cadherin function. The finding that in 
the Rip1Tag2 tumor model, induction of lymphangiogenesis by transgenic expression of the 
lymphangiogenic factor VEGF-C alone is sufficient to induce metastasis supports this idea 
(Mandriota et al., 2001).  
A recent report associated the occurrence of blood filled cavities in RT2;NCAM-/- mice 
with perturbed pericyte-endothelial cell-cell interactions. This study demonstrated that NCAM 
promotes pericyte recruitment during tumor angiogenesis. NCAM-deficient tumors have deficient 
pericyte-endothelial interactions and therefore show increased blood vessel leakage. Furthermore, 
pericyte deficiency per se was shown to cause haematogenous spreading of tumor cells and 
metastasis formation (Xian et al., 2006). Clearly, however, more experiments are needed to 








1.5.1. Function and composition of integrins 
 
The extracellular Matrix (ECM) is composed of an insoluble network of proteins that are 
secreted, assembled and remodeled throughout the lives of cells. Its function is not only to 
provide a shapeable, but still robust scaffold for the organization of cells in tissues. It also exerts 
control on the behavior of cells. Hence, it is able to dictate whether cells will proliferate or 
undergo growth arrest, migrate or remain stationary, or undergo apoptosis (Guo and Giancotti, 
2004).  Integrins are the major receptors for extracellular matrix proteins and the effects of the 
ECM on cells are mainly mediated by members of this large family of cell-surface receptors. By 
binding to ECM, integrins not only mediate adhesion but also organize the cytoskeleton and 
activate intracellular signaling pathways. In vertebrates, integrins also play certain roles in cell-
cell adhesion (Hynes, 2002). 
Each integrin consists of two type-I transmembrane subunits, one α and one β subunit. 
Mammals have a set of 18 α and 8 β subunits that so far are known to assemble in various 
combinations to form 24 distinct integrins (Figure 8). Depending on their composition, integrins 
bind to distinct ECM components: one set (blue in Figure 8) recognizes the tripeptide sequence 
RGD present in molecules such as fibronectin and vitronectin, another set (pink in Figure 8) binds 
to basement membrane laminins. Additionally, there is a set of integrins representing collagen 
receptors, and some recognize both ECM proteins, such as fibronectin, and Ig-CAM cell surface 
receptors, such as VCAM-1. Vertebrates also have a set of leukocyte specific integrins that also 
recognize Ig-superfamily counter-receptors and mediate heterotypic cell-cell adhesion. Both 
subunits of a given αβ integrin determine the ligand specificity and it should be noted that Figure 
8 is a simplified depiction. 
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Figure 8: The integrin family in vertebrates 
8 β subunits can assort with 18 α subunits to form 24 distinct integrins, which can be considered in several 
subfamilies, based on evolutionary relationships (coloring of subunits), ligand specificity and, in the case 
of β2 and β7 integrins, restricted expression on white blood cells. Adapted from (Hynes, 2002). 
 
Interestingly, each integrin seems to have a specialized, unique function. All β subunits 
and 14 α subunits have been knocked-out in mice, and each phenotype is distinct, ranging from 
pre-implantation development block (β1-integrin knock out) through major developmental 
defects, peri-natal lethality and defects in hemostasis, inflammation, angiogenesis as well as 
many others (Hynes, 2002). This indicates that, in spite of the big number of different integrins, 
the function of a particular integrin is non-redundant and therefore cannot be complemented by 
other integrins.  
 
 
1.5.2. Integrin signaling 
 
Integrins signal through the cell membrane in either direction. Extracellular binding 
activity to ECM proteins is dictated from signals arising from within the cells, so called inside-out 
signaling. For example, the main integrin on circulating platelets is αIIbβ3. Importantly, it is 
normally inactive, but upon activation by various stimuli (e.g. thrombin, ADP and others) from 
within the platelets, αIIbβ3 binds to its ligands fibrinogen, van Willebrand factor and fibronectin. 
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If it were not inactive in the place, platelets would bind fibrinogen from the plasma and 
aggregate, leading to thrombosis (Giancotti and Ruoslahti, 1999; Ginsberg et al., 2005).  
As already indicated, all integrin subunits are type I transmembrane proteins with large 
extracellular domains, a single-pass transmembrane (TM) domain and a small cytoplasmic tail. 
The cytoplasmic tails are devoid of enzymatic features, therefore, integrin-signals are transduced 
by adaptor proteins that connect integrins to the cytoskeleton, to the cytpolasmic kinases and 
finally to transmembrane growth factor receptors.  Once an integrin has bound to the ECM, it 
elicits signals that are transmitted into the cell (outside-in signaling). Upon binding, integrins 
cluster in the plane of the cell membrane and associate with a cytoskeletal signaling complex that 
promotes assembly of actin filaments. The re-organization of actin filaments into larger stress 
fibers in turn causes more integrin clustering, enhancing matrix binding. The resulting aggregates 
of ECM proteins, integrins and cytoskeletal proteins are known as focal adhesions (Burridge and 
Chrzanowska-Wodnicka, 1996) and this is what integrins were named after: they serve as 
integrators of the ECM and the cytoskeleton (Giancotti and Ruoslahti, 1999) 
The molecular players involved in integrin signaling are too many, and the networks are 
too complex to be discussed here in detail. Generally, as described in Figure 9, most integrins 
signal through Src-family kinases (SFK) that get recruited and activated via the activation of focal 
adhesion kinase (FAK), which in turn is dependent on the assembly of focal adhesions. FAK also 
activates signaling through phosphatidylinositol 3-kinase (PI3K) and therefore AKT/protein 
kinase B (PKB). Src can phosphorylate p130CAS and paxillin, which engages the Crk-DOCK180 
complex and results in the activation of Rac. FAK also activates extracellular signal-regulated 
kinase (ERK)/mitogen-activated protein kinase (MAPK) by employing the RAP1 guanine 
nucleotide exchange factor (GEF) C3G through Crk, resulting in the activation of ERK/MAPK by 
B-Raf.  
In an alternative pathway, FAK activates ERK/MAPK via the recruitment of the growth 
factor receptor bound-2 (GRB2) and son-of-sevenless (SOS) complex (Schlaepfer and Hunter, 
1998; Cary et al., 1999). Some integrins are able to directly interact with SFKs with their β 
subunits (Arias-Salgado et al., 2003), whereas others are coupled to palmitoylated SFKs (such as 
Fyn and Yes) through their α subunits. The palmitoylated SFKs activate the adaptor SHC, which 
combines with GRB2-SOS to activate ERK/MAPK signaling from Ras (Wary et al., 1996). In 
this pathway, caveolin is needed to facilitate the recruitment of Fyn and Yes (Wary et al., 1998). 
The pathways that integrins activate through SFKs are sufficient to induce cell migration and 
survival signals (see below). 
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Figure 9: Pathways employed by integrin signaling 
Integrins employ several pathways to transduce signals resulting in different cellular behavior: Focal 
adhesion kinase (FAK) can activate (either directly or indirectly) ERK/MAPK via the Grb2/Ras/Raf or the 
Crk/Rap1/B-Raf pathway. Alternative pathways via Rac result in JUN and NFκB activation or AKT/PKB 
activation via PI3K (see text). Adapted from (Guo and Giancotti, 2004). 
 
 
Integrins not only signal on their own; they are also necessary for optimal growth factor 
activation. Integrin clustering and association with the cytoskeleton gives rise to integrin-growth 
factor receptor complexes. Only under appropriate cell attachment conditions, growth factor 
receptors such as platelet derived growth factor receptor (PDGFR), VEGFR, and epidermal 
growth factor receptor (EGFR) are optimally activated by their respective ligands, which 
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1.5.3. The functions of integrin signaling 
 
What are the results of integrin signaling? Integrin signals are essential for cells to 
traverse the cell division cycle (progression through G1). This is, among other factors, mediated 
through cyclin D1 expression, since cells that are not properly attached show suppressed cyclin 
D1 levels. The composition of the ECM is important in this respect: myoblasts, for example, 
proliferate on fibronectin but stop proliferation and form myotubes on laminin, implying that 
integrin signaling also regulates, or at least is necessary, for differentiation. 
Loss of attachment causes apoptosis in many cell types, a phenomenon called anoikis. 
Just like cell growth, anoikis can be regulated in an integrin-specific manner, meaning that 
integrin signaling induces apoptosis in non-attached cells, but gives rise to survival signals in 
properly located cells (Meredith et al., 1993; Frisch et al., 1996). Importantly, most cells in adult 
organisms are not actively dividing, therefore it is likely that other cell adhesion proteins override 
the growth-promoting but not the survival-promoting effects of integrins. This contact inhibition 
of growth, together with integrin-induced anoikis or cell survival respectively, ensures the 
development and maintenance of proper tissue architecture.  
Integrins also regulate cell spreading and migration: a cell that comes in contact with 
ECM usually extends filopodia. Integrins at the tips of these filopodias bind to the ECM and 
induce the formation of focal adhesions. Subsequently, actin-rich lamellipodia are generated and 
the cells spread on the ECM, followed by the full development of focal adhesions and actin stress 
fibers. During cell migration, these same events occur as cells extend lamellipodia and form focal 
adhesions to derive the traction necessary for movement (Giancotti and Ruoslahti, 1999). 
Integrins regulate these events by activating the Rho-family of small guanine nucleotide-binding 
proteins, in which Cdc42 induces filopodia, Rac lamellipodia, and Rho induces focal adhesion 
and associated stress fibers, each of them further controlling the cytoskeleton by associating with 
downstream effectors (Hall, 1998). 
Taken together, integrins can be seen as one class of “master regulators”, being important 
for the establishment and maintenance of tissue architecture.  
 
 
1.5.4. Integrins in tumor progression 
 
As already mentioned in section 1.1 and 1.3, cells that have undergone neoplastic 
transformation are much less dependent on the ECM for their proliferation and survival. To 
eventually form metastases, cancer cells have to undergo critical changes affecting their invasive 
properties. Given the important role of integrins, it is not surprising that in many tumors mutation 
in genes playing a role in integrin signaling have been identified (Guo and Giancotti, 2004). 
 Importantly, despite their relative anchorage independence, tumor cells can still take 
advantage of integrin signals by preferentially expressing integrins that favor proliferation, 
survival and migration. These changes in integrin expression are complex and depend on the 
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tissue of origin of the tumor, its histological type and the stage of progression of the disease 
(Zutter et al., 1995; Albelda et al., 1990; Gladson and Cheresh, 1991). Cell type-dependent 
changes in integrin signaling make it impossible to assign each of the integrins to the “anti-
neoplastic” or “pro-neoplastic” category. It seems that α2β1 and α3β1, at least in some cases, 
suppress tumor progression, whereas αvβ3, αvβ6, and α6β4 often promote it (Guo and Giancotti, 
2004). A recent study, however, demonstrated that β1-integrin is essential for the formation of 
mammary tumors in a mouse model of human breast cancer, but not for the initial stages of 
mammary ductal outgrowth, suggesting that the primary function of β1-integrin is to promote cell 
proliferation (White et al., 2004). 
 As discussed in section 1.3.1, loss of E-cadherin-mediated adhesion is required for 
malignant conversion. Increasing evidence indicates that joint integrin-receptor tyrosine kinase 
(RTK) signaling contributes to disrupting cell-cell adhesion in cancer cells. Blocking β1-integrin 
in a 3D culture of breast carcinoma cells induced these cells to re-assemble adherens junctions 
and deposit a basement membrane, giving rise to acini characterized by a distinct polarity 
(Weaver et al., 1997), whereas over-expression of β1-integrin caused the disruption of adherens 
junction in normal epithelial cells (Gimond et al., 1999).  
Two mechanisms seem to be involved in disrupting cell-cell adhesions: activated RTKs 
and SFKs induce tyrosine phosphorylation of components of the E-cadherin-β-catenin complex 
(see also section 1.3.1). The tyrosine-phosphorylated complex is recognized by the E3 ubiquitin 
protein ligase Hakai and therefore down-regulated by endocytosis (Fujita et al., 2002).  This 
process requires integrin function and FAK phosphorylation in v-Src transformed cells, 
suggesting that v-Src promotes endocytosis of E-cadherin by enhancing integrin signaling 
(Avizienyte et al., 2002). Secondly, integrin signaling operates through SNAIL/SLUG to suppress 
E-cadherin expression and consequently disturb adherens junctions. Both, integrin linked kinase 
(ILK) and in another study SFKs have been implicated in this mechanism (Novak et al., 1998; 
Tan et al., 2001; Zhang et al., 2003) 
 In normal cells, loss of cell-matrix adhesion induces anoikis (see section 1.5.3). 
Resistance to anoikis is essential for metastatic dissemination of tumor cells. FAK promotes the 
survival of cells by signaling through PI3K to AKT/PKB (Frisch et al., 1996; Khwaja et al., 1997) 
and many invasive human cancers have elevated levels of FAK (Gabarra-Niecko et al., 2003), 
which also has been implicated in a more migratory phenotype of cells. FAK also promotes the 
expression of anti-apoptotic and suppression of pro-apoptotic stimuli (Guo and Giancotti, 2004). 
Integrins contribution to tumor progression have been implicated in many more processes, such 
as angiogenesis or matrix remodeling, which is described in great detail elsewhere (Guo and 
Giancotti, 2004; Hood and Cheresh, 2002; Hynes, 2002). 
 Summarizing the effects of integrins in tumor development, it seems that each tumor type 
undergoes characteristic and dynamic changes in integrin expression and function during tumor 
progression. Future studies might uncover the full complexity of these changes. Testing the 
relevance of these changes in integrin expression and signaling in mouse models of cancer could 
open the way to the development of (potentially anti-integrin) compounds for tumor therapy. 
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1.6. Aims of the study 
 
Deletion of NCAM in Rip1Tag2 tumors results in the induction of lymphangiogenesis, 
tissue disaggregation and the formation of metastases. In β tumor cells, NCAM associates with 
FGFR-4 and N-cadherin, thereby the receptor is activated and signaling cascades, leading to the 
activation of β1-integrin and hence cell-matrix adhesion are induced. We therefore wanted to 
investigate whether ablation of β1-integrin function in Rip1Tag2 tumors pheno-copied the NCAM 
deletion.  
 
   Specific research goals: 
 
• To determine whether the in vitro observed 
lack of β1-integrin activation in NCAM 
deleted tumor cells leads to tumor tissue 
disaggregation in vivo, we planned to 
interfere with β1-integrin expression 
specifically in the Rip1Tag2 tumor model. 
 
• Using this approach, we furthermore 
analyzed whether increased 
lymphangiogenesis in NCAM knock-out 
tumors lies downstream of β1-integrin 
inactivation and/or tissue-disaggregation or 
whether it is the result of an alternative, β1-
integrin-independent pathway.  
 
• By interfering with β1-integrin expression 
we furthermore wanted to determine 
whether loss of NCAM-dependent 
activation of β1-integrin alone is sufficient 
to induce the formation of metastasis. 
 
 
• Using specific inhibitors or stimulating reagents on cells and assaying for cell-matrix 
adhesion we wanted to dissect and compare the pathways underlying NCAM and FGF 
induced β1-integrin activation in vitro.  
 
• In co-expression and immunoprecipitation studies, we aimed to investigate whether 
NCAM can associate with and modulate additional receptor tyrosine kinases.
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Neural cell adhesion molecule has been studied mainly in neurons where it influences 
processes, such as neurite outgrowth, axon guidance and pathfinding by homophilic and 
heterophilic interaction with the fibroblast growth factor receptor FGFR-1. We have 
previously shown that NCAM modulates FGFR-4 signaling also in non-neuronal tissues by 
exerting stimulating effects as well as inhibiting ligand-induced signaling. Here, we show that 
NCAM associates with a number of receptor tyrosine kinases (RTKs). In particular, NCAM 
binding to the platelet derived growth factor receptor β (PDGFRβ) represses its activity. Our 
results suggest that NCAM acts as a general modulator of Ig-domain containing RTKs. 
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The neural cell adhesion molecule (NCAM) is a member of the immunoglobulin-like 
superfamily of Ca2+ -independent adhesion molecules (Ig-CAMs; Rutishauser, 1993). Three 
main isoforms of NCAM are produced through alternative splicing of a single gene, namely 
NCAM120, NCAM140 and NCAM180, where the numbers refer the isoforms relative 
molecular weight (Owens et al., 1987). NCAM140 and NCAM180 are single spanning 
transmembrane proteins, in contrast, NCAM120 is linked to the cell membrane via a 
glycophosphatidyl inositol (GPI-) anchor. The N-terminal, extracellular parts of all isoforms 
are composed of five Ig-like domains followed by two fibronectin type III (F3) modules 
proximal to the membrane. The intracellular domain of NCAM180 differs to the one of 
NCAM140 in having an additional, 261 amino acids long insert (Cunningham, 1995). 
Variation of NCAM expression and therefore function of all three isoforms is attained 
through post-translational modifications. For example, the negatively charged sugar polysialic 
acid can be attached to the fifth Ig domain (Fujimoto et al., 2001). Moreover the cytoplasmic 
domains of NCAM140 and NCAM180 can be palmitoylated, which determines the proteins 
association with lipid rafts (Little et al., 1998). 
NCAM is mainly expressed in neuronal tissues, both during development and in the 
adult organism. It is involved in processes such as the migration of neuronal progenitor cells, 
axon growth and pathfinding, synaptic plasticity and long-term potentiation (Walsh and 
Doherty, 1997). The effects of NCAM are mediated through its homophilic binding as well as 
its heterophilic interactions with other Ig-CAMs, extracellular matrix proteins and cell surface 
receptors.  NCAM binding has been shown to affect several intracellular signaling pathways, 
such as the mitogen activated protein kinase (MAPK), phospholipase C-γ (PLC-γ), protein 
kinase C (PKC), phosphatidylinositol 3-kinase (PI3K), diacylglycerol and arachidonic acid 
(reviewed in Povlsen et al., 2003). It has been shown that NCAM association with the 
fibroblast growth factor receptor 1 (FGFR-1) and the resulting induction of signaling cascades 
is crucial for neurite outgrowth in neuronal cells. A recent study identified the interaction 
domains of FGFR-1 and NCAM to be located in the third Ig domain of FGFR-1 and the 
second F3 repeat of NCAM (Kiselyov et al., 2003). 
However, NCAM expression is not only reduced to the nervous system but also 
found in skeletal muscle cells as well as some neuroendocrine tissues (Dickson et al., 1987; 
Rouiller et al., 1990). We have previously shown that NCAM associates with the FGFR-4 in 
fibroblasts and pancreatic β tumor cells (Cavallaro et al., 2001). In these cellular systems, 
NCAM acts as a ligand for FGFR-4, inducing its activation and downstream signaling 
cascades upon ligation with the receptor. In this way, NCAM is able to modulate β1-integrin 
activity and hence cell-matrix adhesion. These findings extended NCAMs function in 
modulating receptor tyrosine kinase (RTK) signaling to another member of the FGFR family 
in non-neuronal tissues. 
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RTK are single transmembrane spanning proteins, all comprising an intracellular 
tyrosine kinase activity and varying extracellular domains, which groups them into several 
subfamilies. The FGFR subfamily is composed of four members, FGFR1-4 (Klint and 
Claesson-Welsh, 1999). Structurally, the extracellular domains are composed of two or three 
Ig-like domains. Similar to the FGFR family, platelet derived growth factor receptors 
(PDGFRα and PDGFRβ) are composed of five Ig-like repeats (Heldin and Westermark, 
1999), whereas other receptors, such a the epidermal growth factor receptor (EGFR) (Ullrich 
and Schlessinger, 1990) or the hepatocyte growth factor receptor (c-Met), do not display these 
structures in their extracellular domain (Giordano et al., 1989). RTKs usually get activated by 
binding to specific ligands, i.e. growth factors. Dimerisation of receptor monomers upon 
ligand binding is a prerequisite for activation of receptor trans-phosphorylation. Upon 
phosphorylation, a number of signal transduction molecules are binding to the receptors 
cytoplasmic tails, triggering a variety of downstream signaling events (Ullrich and 
Schlessinger, 1990). However, as mentioned above, regulation of RTK signaling is also 
achieved by extracellular binding of other factors to RTKs. 
We hypothesized that NCAM could act as a general modulator of RTK signaling by 
interacting with and influencing various members of the RTK family. We show here that 
NCAM can bind to several RTKs. Specifically, NCAM likely acts as a negative regulator of 
PDGFRβ signaling. Our findings extend NCAM’s functions to other RTKs and demonstrate 
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2.2. Materials and Methods 
 
2.2.1. Antibodies and reagents 
 
Anti-FGFR-2 (C-17), FGFR-3 (C-15), FGFR-4 (C-16), PDGFRα (C-20), PDGFRβ 
(958 and P-20,) all from Santa Cruz; anti-V5 (Invitrogen), anti-P-MAPK and MAPK (Sigma), 
anti human NCAM (OB11, Sigma), anti mouse NCAM (5B8, generous gift from U. 
Cavallaro), anti-P-Tyr (PY-20, Transduction Laboratories). PDGF-BB was obtained from 
Sigma, Protein G Sepharose  from Amersham. 
 
 
2.2.2. Tissue culture 
 
HEK 293T cells were grown in DMEM, 10% FCS, 1% Glutamine, 1% 
Penicillin/Streptomycin (Sigma). NIH 3T3 cells were grown in DMEM, 10% CS, 1% 
Glutamine, 1% Penicillin/Streptomycin (Sigma). 
 
 
2.2.3. Stable transfection of NIH 3T3 cells 
 
For constructing a shRNA vector against mouse N-CAM: Forward primer: 5’-
GATCCCCGTACAAGGCTGAGTGGAAGTTCAAGAGACTTCCACTCAGCCTTGTACT
TTTTGGAAA-3; reverse primer: 5’-AGCTTTTCCAAAAAGTACAAGGCTGAGTGG-
AAGTCTCTTGAACTTCCACTCAGCCTTGTACGGG-3’; after annealing, the sequence 
was cloned into pSuperRetro-neo. As control,  a sequence directed against human E-cadherin 
was used (forward primer: 5'-GATCCCCATCTGAAAGCGGCTGATACT-
TCAAGAGAGTATCAGCCGCTTTCAGATTTTTTGGAAA-3' , reverse primer: 5'-
AGCTTTTCCAAAAAATCTGAAAGCGGCTGATACTCTCTTGAAGTATCAGCCGCTT
TCAGATGGG-3'), after transfection, cells were selected using 200 ng/ml G418 (Sigma),  
resistant clones were expanded for further analysis. 
 
 
2.2.4. Cell stimulation, protein extraction and Western Blot 
 
NIH3T3 cells were cultured in 6-well plates in medium containing serum, then 
serum-starved overnight in serum-free medium. The day of the experiment, cells were 
stimulated with 30 ng/ml PDGF-BB for the time indicated. After the stimulation, cells were 
lysed in lysis buffer (20 mM Tris/HCl pH 8.0, 160 mM NaCl, 1 mM CaCl2, 10 µg/ml 
aprotinin, 1% Triton X-100, 1 µg/ml leupeptin, 1 mM PMSF, 10 mM NaF, and 1 mM sodium 
orthovanadate). Following centrifugation, the protein concentration of cell lysates was 
determined using the Bio-Rad DC Protein Assay (BioRad, Hercules, CA). Proteins were 
resolved by SDS-PAGE and transferred to nitrocellulose membranes (Milipore). Proteins of 
interest were visualized using specific antibodies, followed by peroxidase-conjugated 
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For immunoprecipitation analyses, cell lysates (1 mg) were pre-cleared with non-
immune IgG (Sigma) plus Protein G-Sepharose (Amersham). Lysates were then incubated 
with specific antibodies overnight at 4 °C, followed by the addition of Protein G-Sepharose 
and further incubation for 2 h at 4 °C. After four washing steps in lysis buffer, proteins were 
eluted with Laemmli buffer and resolved by SDS-PAGE, followed by immunoblotting. 
 
 





2.3.1. NCAM associates with all members of the FGFR family 
 
We previously showed that all three NCAM isoforms are found in a complex with 
FGFR-4 in fibroblastic L cells (Cavallaro et al., 2001). To investigate whether NCAM is also 
found in association with FGFR-4 in other cell types, FGFR-4 and either of the three NCAM 
isoforms (NCAM120, NCAM140 and NCAM 180) were transiently expressed in human 
embryonic kidney (HEK 293T) cells. Complex formation was assayed by investigating 
proteins associated with the FGFR-4 in co-immunoprecipitation experiments or, conversely, 
by identifying proteins that bind to NCAM. When immunoprecipitated with antibodies 
directed against FGFR-4, all three NCAM isoforms were found to bind to FGFR-4 (Figure 
1A). The same observation was made in the reverse experiment: All three NCAM isoforms 
were able to co-immmunoprecipitate FGFR-4 (Figure 1B). Albeit expression levels of 
NCAM180 were high in both experiments, this isoform was least efficient in binding FGFR-
4. These results confirm our previous observations that all NCAM isoforms can associate 
with FGFR-4 in various cellular system 
 
Figure 1: All three NCAM isoforms associate with the FGFR-4 
Immunoblotting analysis following immunoprecipitations of lysates transfected with FGFR-4 and 
NCAM 120 (left panel), FGFR-4 and NCAM 140 (middle panel) or FGFR-4 and NCAM 180 (right 
panel). A) Lysates were incubated with an antibody against FGFR-4 (IP R4) or an unrelated antibody 
(IP contr). B) Lysates were incubated with an antibody directed agains NCAM (IP NCAM) or an 
unrelated antibody (IP contr). Input: total lysate for expression control. 
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In addition to FGFR-4, a direct interaction between FGFR-1 and NCAM was recently 
demonstrated (Kiselyov et al., 2003). We thus hypothesized that NCAM can bind to all 
members of the FGFR family. To test this, FGFR-3 (Figure 2, upper panel) and FGFR-2 
(Figure 2, lower panel) were co-expressed with the three NCAM isoforms in HEK 293T cells.  
Using anti-FGFR-2 or FGFR-3 antibodies for immunoprecipitation, all three NCAM isoforms 
were found in a complex with the respective FGFR (Figure 2). Hence, we could observe that 




Figure 2: NCAM binds to FGFR-2 and FGFR-3 
HEK 293T cells were transiently transfected with cDNA for FGFR-3 (upper panel), FGFR-2 (lower 
panel) and the three major NCAM isoforms. Co-immunoprecipitations using anti-FGFR-3 antibodies 
(upper panel) or anti-FGFR-2 antibodies (lower panel) and subsequent Immunoblotting analysis for 
NCAM was performed. IP R3, IP for FGFR-3; R2/120, R2/140, R2/180, lysates expressing FGFR-2 




2.3.2. NCAM associates with PDGFRβ 
 
All FGFR family members consist of an extracellular domain containing Ig-like 
repeats. Interaction between NCAM and FGFR-1 is dependent of the third Ig-domain of the 
receptor. We therefore investigated if other Ig-domain containing RTKs can bind to NCAM. 
HEK 293T cells were transfected with cDNAs coding for either of the two platelet derived 
growth factor receptors PDGFRα and PDGFRβ, and NCAM140. Furthermore we tested 
complex formation between NCAM and two receptors that do not contain Ig repeats, the 
hepatocyte growth factor receptor (c-Met) and the epidermal growth factor receptor (EGFR). 
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In repeated experiments we never found c-Met or EGFR to associated with 
NCAM140 (data not shown). However, both PDGFRα and PDGFRβ were found to bind 
NCAM140 (Figure 3A and Figure 3B). PDGFRβ binding to NCAM was not restricted to the 
NCAM140 isoform, since NCAM120 and NCAM180 could also be immunoprecipitated 
together with PDGFRβ (Figure 3C).  Taken together, PDGFRα and PDGFRβ can form a 

















Figure 3 A and B: NCAM associates with PDGFRα and PDGFRβ 
Western blot analysis of co-immunoprecipitations (co-IPs) of HEK 293T cells expressing either a 
control plasmid (Mock), PDGFRα and NCAM140 (Rα/140, Figure 3A) or PDGFRβ and NCAM140 
(Rβ/140, Figure 3B). IP Rα, IP Rβ, IP using anti-PDGFRα or anti-PDGFRβ antibodies; IP contr, IP 









Figure 3C: NCAM associates with PDGFRα and PDGFRβ 
HEK 293T were transfected with a control plasmid (Mock), PDGFRβ and NCAM120 (Rβ/120), 
PDGFRβ and NCAM140 (Rβ/140) or PDGFRβ and NCAM180 (Rβ/180). IPs were performed using 
either a specific antibody (IP spec) against PDGFRβ (upper panel), NCAM  (lower panel) or an 




2.3.3. NCAM reduces tyrosine phosphorylation on the PDGFRβ 
 
The complex formation of PDGFRβ and NCAM, but not of PDGFRα and NCAM, 
was confirmed in a number of alternative cellular systems, such as L-cells and NIH 3T3 
fibroblasts (data not shown) and therefore the effects of NCAM on PDGFRβ signaling was 
further investigated. We first examined whether the cellular tyrosine phosphorylation pattern 
was altered in cells expressing PDGFRβ  in the presence or absence of NCAM. The 
experiments were performed under serum starvation (no PDGF-BB) and receptor stimulation 
(addition of PDGF-BB) conditions. Phospho-tyrosine signals could only be detected in cells 
expressing PDGFRβ. Interestingly, the signal was reduced in cells co-expressing PDGFRβ 
and NCAM. Upon PDGF-BB treatment, phosphos-tyrosine levels were increased. However, 
NCAM reduced phospho-tyrosine levels equally in serum free or PDGF-BB-treated cells. 
Thus, it seems that tyrosine phosphorylation reduction by N-CAM is not specific for ligand 
stimulated receptors (Figure 4A, 1st panel). The total amounts of PDGFRβ (Figure 4A, 2nd 
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panel) and NCAM140 (Figure 4A, 3rd panel) were unchanged, suggesting that the observed 




















Figure 4A: Phosphotyrosine levels are reduced upon NCAM140 expression 
Lysates from HEK 293T cells transfected with the indicated cDNAs and grown in the absence (serum 
free) or presence of PDGF-BB were analyzed for the expression levels of the indicated proteins. P-Tyr, 




To investigate whether the alleviated phospho-tyrosine levels correlated with a 
decrease in PDGFRβ activation, the PDGFRβ-specific phosphorylation pattern was analyzed 
in the presence or absence of NCAM. As shown in Figure 4B, tyrosine phosphorylation levels 
of PDGFRβ were slightly lessend in cells that co-express NCAM as compared to PDGFRβ 
solely expressing cells. Similar to our previous observation, this could be observed in both, 
serum free and PDGF-BB stimulated conditions, confirming that the presence of the ligand 
does not alter the effects exhibited by NCAM. Taken together, NCAM associates with 
PDGFRβ in a ligand independent manner and negatively influences its tyrosine 
phosphorylation. 
 


















Figure 4B: Reduced tyrosine phosphorylation levels of PDGFRβ in the presence of NCAM 
Lysates were prepared from HEK 293T grown in the absence (SF) or presence (BB) of PDGF-B, 
transfected with a control plasmid (Mock), NCAM140 (140),  PDGFRβ (Rβ) or PDGFRβ and 
NCAM140 (140/ Rβ). IPs were performed using a specific antibody against PDGFRβ and analyzed by 
immunoblotting with the indicated antibodies. 
 
 
2.3.4. Loss of NCAM enhances PDGF-BB induced activation of MAPK 
 
Forced expression of proteins usually yields high amounts of the respective protein. 
In the case of RTKs, this often leads to receptor phosphorylation by dimerisation in absence 
of an appropriate stimulus, which was also observed in the case of PDGFRβ expression under 
serum starved conditions (Figure 4A and Figure 4B). Furthermore, not every receptor 
molecule associates with NCAM and vice versa, not every NCAM molecule is engaged in 
receptor binding, since both, NCAM or PDGFRβ were also found in cleared lysates after 
immunoprecipitation (data not shown).  Therefore, detecting the effect of NCAM on a sub-
population of all PDGFRβ proteins might be undermined by the NCAM-unbound fraction of 
PDGFRβ. These drawbacks together with the fact that HEK 293T cells are not PDGF-BB 
responsive, forced us to choose an alternative approach to investigate the effect of N-CAM on 
PDGFRβ signaling.  
Interfering with NCAM expression using an shRNA approach in NIH 3T3 mouse 
fibroblast cells allowed for analyzing NCAMs influence on PDGFRβ signaling in a system 
expressing physiological levels of both proteins. We generated stable clones expressing three 
different shRNAs specific for mouse NCAM. One of the tested shRNAs was effective in 
degrading NCAM mRNA, leading to almost quantitative loss of NCAM protein expression 
(clone 3-1, Figure 5, upper panel). As control, an unrelated shRNA was stably introduced into 
NIH 3T3 cells (clone 6-3, Figure 5), having no effect on NCAM expression levels. 
Stimulating NIH 3T3 cells with PDGF-BB results in extracellular signal-regulated kinase1 
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and 2 (Erk1/2, referred to MAPK hereafter) activation and can therefore be used to analyze 
PDGFRβ signaling. We used clone 6-3 and clone 3-1 to compare PDGFRβ signaling upon 
stimulation in the presence and absence of NCAM.  When grown under serum free 
conditions, loss of NCAM resulted in slightly increased levels of phosphorylated Erk1/2 (P-
MAPK hereafter) (lane 0 in Figure 5, middle panel). Upon addition of PDGF-BB, P-MAPK 
levels were induced in control cells, showing highest MAPK activation after ten minutes of 
ligand addition and dropping to almost serum starved levels after 30 minutes. In contrast, in 
NCAM-deficient cells, P-MAPK was induced to maximum level already after five minutes 
and activation was sustained throughout the entire duration of the time course. Furthermore, 
over all P-MAPK levels were increased in cells having lost NCAM expression. These results 
indicate that N-CAM negatively affects PDGFRβ-induced MAPK-signaling in the absence 















Figure 5: NCAM reduces PMAPK levels in NIH 3T3 cells 
Immunoblotting analysis of cells expressing control shRNA (clone 6-3) and shRNA against mouse 
NCAM (clone 3-1). 0, 5, 10, 15, 30: minutes of incubation with PDGF-BB. S, serum control.  
 
 
 To determine whether the induction of MAPK was a specific consequence of NCAM 
down-regulation and did not reflect an unspecific effect resulting from the shRNA, human 
NCAM140 tagged with the V5 epitope was transiently re-introduced into clone 3-1. 
Transfection efficacy was rather low since only about 5-10% of all cells expressed the V5-tag 
and thus human NCAM140 (Figure 6, lower left panel). When the cells were stimulated with 
PDGF-BB, P-MAPK levels were not significantly reduced upon re-expression of NCAM 
(Figure 6, 3rd right panel). Furthermore, the kinetics of the stimulation was similar to the 
original, NCAM deficient clone 3-1. However, since only a small percentage of all analyzed 
cells were successfully transfected, the result of NCAM re-introduction may not be 
detectable. Therefore, this experiment is not conclusive. 





Figure 6: Partial re-introduction of NCAM does not result in P-MAPK reduction 
Right panel: Immunoblotting analysis with the indicated antibodies of clone 3-1 transiently transfected 
with human NCAM140 cDNA in comparison to original clone 3-1 and control clone 6-3. 0, 5, 10, 15, 
30: minutes of incubation with PDGF-BB. Left panel: control of transfection efficacy. Up: Cell density 
at time point of harvesting cells, determined by light microscopy.  Down: Immunofluorescence staining 

















A direct interaction between NCAM and FGFR-1 and 4 was recently demonstrated 
by others and our group (Kiselyov et al., 2003; Francavilla et al., in preparation). In the case 
of FGFR-1, the interaction is dependent on the third Ig domain of the receptor. Among the 
huge family of RTKs, several receptors carry varying numbers of Ig-domains in their 
extracellular parts. Members of the FGFR family for instance are composed of two (Ig 
domain II and III) or three Ig domains (Ig domain I, II and III), depending on the particular 
splice variant (Klint and Claesson-Welsh, 1999).  Other receptors such as PDGFRα and 
PDGFRβ are characterized by five Ig domains (Heldin and Westermark, 1999) or, in the case 
of the vascular endothelial growth factor receptor (VEGFR) family, seven Ig domains. We 
show here that all NCAM isoforms are able to associate with three members of the FGFR 
family (FGFR-2, -3 and -4), as well as PDGFRα and PDGFRβ. The interaction of NCAM 
and RTKs seems to be dependent on the presence of an Ig domain, since RTKs lacking this 
structural feature (EGFR and c-MET) cannot associate with NCAM.  In next steps, it will be 
important to investigate if VEGFRs are also interacting with NCAM to support the idea that 
NCAM can act as a ligand for Ig domain containing RTKs. Furthermore, the identification of 
the exact domain or structure of Ig domain III on FGFR-1 necessary for NCAM binding 
might allow to identify additional binding proteins of NCAM. 
In L-cells, stimulation of the FGFR-4 by NCAM or FGF leads to increased cell-
matrix adhesion in a MAPK dependent manner. Using this assay it was recently shown that in 
the absence of FGF, N-CAM acts on FGFR-4 in a stimulating way, inducing MAPK 
activation. However, NCAM acts as a negative regulator of FGF-induced MAPK activation 
and subsequent cell-matrix adhesion (Francavilla et al., in preparation, Chapter 3 in this 
work). We do not know if NCAM binding to FGFR-2 and 3 influences the receptor’s activity 
in a similar way as observed for FGFR-4. Using a system that is based on the forced 
expression of RTKs is sub-optimal to study signaling events, since the un-physiological 
receptor-levels lead to auto-phosphorylation and hence activation of RTK signaling in the 
absence of appropriate stimuli. It will therefore be crucial to identify or generate an 
appropriate system to unravel the influence of NCAM on FGFR-2 and FGFR-3 signaling. 
Several experiments indicate that NCAM acts as a negative modulator of PDGFRβ 
signaling. Co-expression of NCAM and PDGFRβ leads to reduced tyrosine phosphorylation 
of the receptor, both, in the absence and presence of PDGF-BB. Furthermore, interfering with 
NCAM function in NIH 3T3 cells influenced the kinetics and levels of PDGF-BB stimulation. 
Whereas in the absence of NCAM the ligand elicits a strong, sustained P-MAPK response, 
the presence of NCAM allows only a short, transient and weaker activation of MAPK by 
PDGF-BB. This is very similar to what can be observed in FGF induced FGFR-4 signaling in 
L-cells (Francavilla et al., in preparation, Chapter 3) and suggests that NCAM influences 
PDGFRβ similarly to FGFR-4. However, in contrast to FGFR-4 signaling, NCAM does not 
induce PDGFRβ signaling in the absence of PDGF-BB. 
The specificity of the results obtained with shRNA transfected NIH 3T3 cells remains 
to be confirmed. To exclude that the observed effects on PDGFRβ signaling are due to 
unspecific effects of the transfected shRNA, we currently try to establish stable expression of 
2. NCAM binds to the PDGFRβ and potentially reduces its activity 
 
 39
human NCAM140 in the NCAM-deficient clone 3-1. The finding that NCAM associates with 
all FGFR proteins as well as PDGFRα and PDGFRβ indicates that NCAM might act as a 
general RTK signaling modulator in a variety of cell types. Furthermore, the results described 
here and in Chapter 3 extend NCAMs function from stimulating RTKs to also inhibiting 
ligand induced RTK signaling. Future work will focus on the identification of suitable cellular 
systems to dissect the distinct effects of NCAM on the respective RTK. 
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Neural cell adhesion molecule (NCAM) mediates cell-cell adhesion in the central 
nervous system. However, NCAM is also expressed in non-neural tissues where its function 
has in most parts remained elusive. Using a transgenic mouse model of pancreatic β cell 
carcinogenesis (Rip1Tag2), we have previously reported that NCAM stimulates cell-matrix 
adhesion by activating fibroblast growth factor receptor (FGFR) signaling. Here, we 
demonstrate that the direct binding of NCAM to FGFR is necessary and sufficient for 
triggering FGFR activity, which results in mitogen-activated protein kinase (MAPK)-
mediated cell-matrix adhesion. Moreover, our studies reveal that NCAM and FGFs elicit 
distinct FGFR-mediated signaling cascades which account for the differential cell responses 
observed with the two molecules. In addition, NCAM negatively regulates FGF-induced cell-
matrix adhesion, cell proliferation and MAPK activation. Our results indicate an unexpected 
role of NCAM in modulating FGFR functions, thus introducing a novel type of control 
mechanism for receptor tyrosine kinase activity. 









Neural cell adhesion molecule (NCAM) belongs to the immunoglobulin-like 
superfamily of adhesion molecules (Ig-CAMs), and is a cell surface glycoprotein involved in 
calcium-independent intercellular adhesion. The extracellular portion of NCAM contains five 
Ig-like domains (Ig1-5) and two fibronectin type-III (F3) repeats. Alternative splicing yields 
three main NCAM isoforms, two of which are endowed with a transmembrane and a 
cytoplasmic region (NCAM140 and 180), while NCAM120 is linked to the membrane 
through a glycosylphosphatidyl inositol (GPI) anchor (reviewed in Walmod et al., 2004). 
Posttranslational modifications of the protein add further complexity to NCAMs expression 
pattern and function. In particular, the NCAM ectodomain can be polysialylated in a time and 
space-dependent manner, and this process induces a shift in NCAM function from pro-
adhesive to pro-migratory (Angata and Fukuda, 2003). 
NCAM is widely expressed in the central nervous systems, where it plays an 
important role in various processes, both during embryonic development and in adulthood 
(reviewed in Hinsby et al., 2004). Indeed, NCAM is involved in the migration of neural 
progenitor cells, axonal growth and pathfinding, synaptic plasticity and long-term 
potentiation. At the cellular level, NCAM exerts these functions by controlling intercellular 
recognition and adhesion, neurite outgrowth, cell migration, proliferation and survival. These 
events are triggered by the homophilic interaction of NCAM molecules on adjacent cells as 
well as by the heterophilic binding of NCAM to other Ig-CAMs, extracellular matrix 
components, and cell surface receptors. NCAM’s homophilic and heterophilic interactions 
affect a complex network of signaling cascades, which involve many crucial pathways, such 
as mitogen-activated protein kinases (MAPK), phospholipase C-γ  (PLCγ), diacylglycerol and 
arachidonic acid, protein kinase C (PKC), and phosphatidyl inositol 3-kinase (PI3K) 
(reviewed in Walmod et al., 2004). 
Pioneering studies performed by the group of P. Doherty and F. Walsh have 
highlighted a functional interplay between NCAM and the fibroblast growth factor receptor 
(FGFR) in neuronal cells, which underlies NCAM-dependent neurite outgrowth (Walsh and 
Doherty, 1997). Further support for these results came from surface plasmon and nuclear 
magnetic resonance studies that have demonstrated a direct binding of NCAM to FGFR and 
identified the interaction domains in the second F3 repeat of NCAM and the third Ig domain 
of FGFR (Kiselyov et al., 2003). We have confirmed and extended the NCAM/FGFR 
interplay in non-neuronal and tumor cells, such as pancreatic beta tumor cells and fibroblasts, 
implying that it is not restricted to the nervous system (Cavallaro et al., 2001). Our data have 
revealed that the formation of the NCAM/FGFR complex induces FGFR autophosphorylation 
and stimulates an FGFR-dependent signaling cascade that leads to the modulation of β1-
integrin-mediated cell-matrix adhesion. Interfering with this process by abrogating the 
expression of NCAM in a transgenic mouse model of β cell tumorigenesis resulted in the 
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disruption of the tumor tissue architecture, tumor-associated lymphangiogenesis, and lymph 
node metastasis (Perl et al., 1999; Cavallaro et al., 2001; Crnic et al., 2004). These and other 
studies imply that the cross-talk between adhesion molecules and receptor tyrosine kinases 
has important implications and that its dysregulation can play a pathogenetic role in diseases 
such as cancer and neurological disorders (Cavallaro and Christofori, 2004). 
The intracellular signaling pathways elicited by the NCAM/FGFR complex and their 
impact on cellular physiology have been elucidated only to a certain extent, and all the 
information available so far derives from studies on neuronal cell types. In particular, it has 
been shown that, upon NCAM binding to FGFR, a number of intracellular effectors are 
recruited to the phosphorylated residues of the FGFR’s cytoplasmic tail. Among these, PLCγ 
becomes activated when bound to FGFR and then cleaves phosphatidylinositol 4,5-
biphosphate to generate inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). While IP3 
induces an increase in intracellular Ca2+ concentration, DAG can either activate PKC or be 
converted into arachidonic acid (Walmod et al., 2004). In neurons, it has been shown that the 
cytoplasmic tail of NCAM180 and 140 binds to and activate the PKCβII isoenzyme via 
spectrin, a scaffolding protein that contributes to the organization of membrane microdomains 
and to the anchorage of membrane proteins to the cytoskeleton (Leshchyns'ka et al., 2003). 
The formation of this NCAM/spectrin/PKCβII complex was reported to be FGFR-dependent. 
PKC acts as an important nodal point in the signaling cascade elicited by the NCAM/FGFR 
interplay: it activates the neuritogenic protein GAP-43 (involved in signaling and in 
cytoskeletal rearrangements) and it can also stimulate Raf kinase activity. The latter activity 
enables PKC to link the NCAM/FGFR complex to the Raf-MEK-MAPK pathway. Notably, 
homophilic NCAM interactions, which underlie NCAM-mediated cell-cell adhesion, also 
elicit MAPK activation via non-receptor tyrosine kinases, such as pp60c-src or focal adhesion 
kinase (FAK). However, the mutual influence between the signaling cascades elicited by 
NCAM-mediated intercellular adhesion and homophilic interaction and those downstream of 
the NCAM-induced FGFR activation remains elusive. Here, we report novel implications of 
the NCAM/FGFR cross-talk, by showing that i) the direct binding of NCAM to FGFR is 
necessary and sufficient to stimulate MAPK-dependent cell-matrix adhesion; ii) NCAM and 
FGF activate FGFR signaling in a distinct manner, i.e. they induce different FGFR-mediated 
pathways; and iii) NCAM can also act as a negative regulator of the cellular response to FGF 
stimulation. Our results highlight a novel, NCAM-dependent mechanism for the modulation 
of FGFR activity. 
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3.2. Experimental Procedures 
 
 
3.2.1. Cell lines and reagents 
 
NCAM-null and NCAM-positive β tumor cells were isolated from the pancreatic 
tumors of Rip1Tag2;NCAM-/- or NCAM+/+ mice and cultured as previously described 
(Cavallaro et al., 2001). Mouse fibroblastic L cells were maintained in DMEM, 10% fetal calf 
serum, L-glutamine and antibiotics. FGF-1 and FGF-2 were purchased from Peprotech 
(London, UK). Heparin, PMA and arachidonic acid were purchased from Sigma (St. Louis, 
MO). The FGFR inhibitor PD173074 (Skaper et al., 2000) was kindly provided by Pfizer 
(Groton, CT). The PKCβII inhibitor CGP53353 was kindly provided by D. Fabbro (Novartis, 
Basel, Switzerland). The MEK inhibitor PD98059 and the broad-spectrum PKC inhibitor 
Calphostin C were from Sigma. The PKC α/γ inhibitor HBDEE and  the Src inhibitor PP1 
were from Calbiochem. Antibodies: mouse anti-phospho-Erk1/2, rabbit anti-phospho-FRS2 
and rabbit anti-phospho-Src (recognizing the activated form of most Src kinases) were from 
Cell Signaling Technology (Danvers, MA); rabbit anti-Erk1/2 was from Sigma; rabbit anti-
PKCα and anti-PKCβII, rabbit anti-FRS2 and mouse anti-Src kinases were from Santa Cruz 
Biotechnologies; rabbit anti-phospho-PKCβII was from Abcam (Cambridge, UK); mouse 
anti-NCAM was from BD Biosciences (San Jose, CA). The pIg3 vectors containing the 
cDNA for the ectodomain of human NCAM, either full-length or with the deletion of the 
second F3 module (∆FN2), fused to the Fc fragment of human IgG, were kindly provided by 
L. Needham (Duke University). The vectors were used to transiently transfect HEK 293 cells, 
and the recombinant proteins were purified from the conditioned medium of transfected cells 
using Protein G-Sepharose chromatography. The FGL peptide from the second F3 module of 
NCAM and its mutated version carrying two alanine substitutions (FGLmut; Kiselyov et al., 
2003) were a generous gift from ENKAM Pharmaceuticals (Copenhagen, Denmark). 
 
 
3.2.2. Stable transfection of L cells 
 
The cDNA for mouse NCAM140 was subcloned into the pcDNA3.1 expression 
vector (Invitrogen). L cells were transfected with the pcDNA-NCAM plasmid (L-NCAM) or 
with the empty vector (L-mock) using Lipofectamine 2000, followed by selection with 0.8 
mg/ml G418 (Invitrogen) and cloning by limiting dilution. 
 
 
3.2.3. Cell stimulation, protein extraction and Western Blot 
 
Cells were cultured in 6-well plates in DMEM with 10% FCS, then serum-starved 
overnight in serum-free medium. The day of the experiment, cells were stimulated with the 
following molecules at the indicated concentrations: 20 µg/ml NCAM-Fc, 20 µg/ml ∆FN2-
Fc, 20 µg/ml FGL or FGLmut, 20 ng/ml FGF-1 plus 10 µg/ml heparin, 20 ng/ml FGF-2. If not 
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indicated otherwise, cells were stimulated for 10 minutes. When needed, cells were pre-
incubated for 1-2 hours with specific inhibitors at the following concentrations: 100 nM 
PD173074, 25 µM PD98059, 10 µM CGP53353, 100 µM HBDEE, 400 nM Calphostin C, 20 
µM PP1. Control cells were pre-incubated with vehicle alone. After the stimulation, cells 
were lysed in lysis buffer (20 mM Tris/HCl pH 8.0, 160 mM NaCl, 1 mM CaCl2, 10 µg/ml 
aprotinin, 1% Triton X-100, 1 µg/ml leupeptin, 1 mM PMSF, 10 mM NaF, and 1 mM sodium 
orthovanadate). Following sonication and centrifugation to remove cell debris, the protein 
concentration of cell lysates was determined using the Bio-Rad DC Protein Assay (BioRad, 
Hercules, CA). Proteins were resolved by SDS-PAGE and transferred to nitrocellulose 
membranes (Protran, Biosciences). Proteins of interest were visualized using specific 
antibodies, followed by peroxidase-conjugated secondary antibodies and by an enhanced 





For immunoprecipitation analyses, cell lysates (2 mg) were pre-cleared with non-
immune IgG (Sigma) plus Protein G-Sepharose (Pharmacia, Uppsala, Sweden). Lysates were 
then incubated with specific antibodies overnight at 4°C, followed by the addition of Protein 
G-Sepharose and further incubation for 2 h at 4°C. After four washing steps in lysis buffer, 
proteins were eluted with Laemmli buffer and resolved by SDS-PAGE, followed by 
immunoblotting. 
 
3.2.5. Cell adhesion assays 
 
Matrix adhesion assays were performed on collagen type-IV, a substrate that 
mediates NCAM-dependent cell adhesion (Cavallaro et al., 2001). Twenty-four well plates 
were coated with 5 µg/cm2 of mouse collagen IV (BD Biosciences). Cells cultured in 6-well 
plates were stimulated with appropriate compounds, and 105 cells were seeded in 24-well 
plates coated with 4 mg/cm2 of collagen IV. After 2 hours, non-adherent cells were removed 
by washing with PBS. Adherent cells were fixed for 30 minutes with 2% formalin, then 
stained with crystal violet, washed and air-dried. Bound dye was solubilized with 10 % acetic 
acid and absorbance measured at 595 nm. Cell-free wells served as blanks. The assays were 
performed in quadruplicate and repeated at least three times. 
 
 
3.2.6. Cell proliferation 
 
L cells were seeded in triplicate on 24-well plates at 5x103 cells/well, serum-starved 
overnight and treated for 4 days with 10% fetal calf serum or 20 ng/ml FGF-2, which were 
added every 24 hours. At each time point, cells were washed with PBS, fixed and stained with 
crystal violet as described for the adhesion assay. The absorbance at 595 nm was measured, 
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and the ratio between stimulated and non-stimulated L cells was determined for each time 
point. The assays were performed in quadruplicate and repeated at least three times. 






3.3.1. NCAM-induced cell-matrix adhesion requires the binding of NCAM to FGFR. 
 
We have previously reported that membrane-bound NCAM promotes neurite 
outgrowth and cell-matrix adhesion in pancreatic β tumor cells isolated from the Rip1Tag2 
transgenic mouse model of β cell tumorigenesis (Cavallaro et al., 2001). Interestingly, similar 
effects were obtained by treating NCAM-/- β tumor cells with the soluble extracellular 
portion of NCAM fused to the Fc fragment of human IgG (Figure 1A). The Fc fragment alone 
had no effect on cell adhesion (not shown). To verify the cell type-specificity of NCAM 
functions, we stably transfected L cells, a fibroblastic cell line which expresses no NCAM 
(Cavallaro et al., 2001), with NCAM140, and subjected the cells to adhesion assays. As 
shown in Figure 1B, NCAM expression stimulated the adhesion of L cells to collagen IV.  
Moreover, by analogy to β tumor cells, soluble NCAM-Fc promoted matrix adhesion 
of mock-transfected L cells (Figure 1C), while very little effect was obtained in NCAM-
expressing cells (not shown). These data imply that both the anchorage of NCAM to the cell 
surface and its cytoplasmic tail are dispensable for NCAM-induced cell-matrix adhesion, and 
that this functional property of NCAM is not restricted to β tumor cells. 
Both NCAM-/- β tumor cells and L cells lack endogenous NCAM. Hence, the pro-
adhesive effect of NCAM-Fc is not due to homophilic NCAM-NCAM interactions but rather 
implicates a cross-talk of soluble NCAM-Fc with other effectors. We have previously 
reported that NCAM-induced neurite outgrowth and matrix adhesion in β tumor cells are 
mediated by FGFR signaling (Cavallaro et al., 2001). These observations were now extended 
to L cells, where the FGFR inhibitor PD173074 repressed NCAM-dependent matrix 
adhesion, confirming the NCAM/FGFR crosstalk (Figure 1B). NCAM and FGFR have been 
previously found to co-immunoprecipitate from whole cell lysates (Cavallaro et al., 2001), yet 
the implications of their direct physical interaction have remained elusive. To address this 
issue, we took advantage of the recent mapping of the FGFR-binding motifs in the second F3 
repeats of the NCAM’s extracellular portion (Kiselyov et al., 2003), and treated NCAM-/- β 
tumor cells with a version of NCAM-Fc lacking this domain (∆FN2-Fc). As shown in Figure 
1A, ∆FN2-Fc failed to induce cell adhesion to collagen IV. In agreement with our previous 
observations (Cavallaro et al., 2001), FGF-1 was able to induce cell-matrix adhesion almost 
to the same extent as full-length NCAM-Fc. FGFR activation promoted matrix adhesion also 
in fibroblastic L cells, as demonstrated by stimulation with FGF-2 (Figure 1C). The latter was 
used in all the experiments with L cells because this cell type, unlike β tumor cells, is more 
responsive to FGF-2 than FGF-1 (CF and UC, unpublished observations). As expected, the 
FGFR inhibitor PD173074 repressed the adhesion of L cells stimulated with FGF-2. The 
inhibitory effect of PD173074 was specific for FGFR signaling, since the drug did not affect 
the basal adhesion activity of L cells (Figure 1C). By analogy to β tumor cells, ∆FN2-Fc 
failed to promote L cell adhesion to collagen IV. In addition, NCAM-Fc-induced adhesion of 
L cells was repressed by PD173074 (Figure 1C), thus confirming the essential role of FGFR 
in NCAM-mediated signaling. Furthermore, matrix adhesion of L cells was also stimulated by 
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the FGL peptide, which mimics NCAM binding to and activation of FGFR, while a mutated 
version of the peptide unable to bind to FGFR (Kiselyov et al., 2003) showed no effect 
(Figure 1C). Together, the results indicate that the direct association of NCAM to FGFR is 
not only necessary but also sufficient for NCAM-dependent cell-matrix adhesion. 
 
 
Figure 1: NCAM induces cell-matrix adhesion by binding to FGFR 
 NCAM-/- β tumor cells (A) or L cells (B and C) were stimulated for 10 minutes with NCAM-Fc, ∆FN2-
Fc, FGL or FGFmut, FGF-1, or FGF-2. When needed, cells where pre-incubated with PD173074 or 
DMSO alone for 2 hours prior to the stimulus. After the treatment, cells were subjected to adhesion 
assays on collagen IV-coated wells. Adherent cells were counted, and the results are presented 
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3.3.2. NCAM-induced cell-matrix adhesion is mediated by Erk1/2 activation 
 
We and others have shown that various signaling pathways are implicated in neurite 
outgrowth stimulated by NCAM (Cavallaro et al., 2001; Walmod et al., 2004). However, the 
intracellular cascade(s) that underlies NCAM-induced cell-matrix adhesion has been only 
partially unraveled. Since the activation of extracellular signal-regulated kinase 1 and 2 
(Erk1/2) is one of the most prominent effects elicited by membrane-bound NCAM (Cavallaro 
et al., 2001), we initially focused on this signal transduction pathway. To elucidate the role of 
Erk1/2 in NCAM-dependent adhesion, NCAM-/- β tumor cells were treated with NCAM-Fc 
in the presence of the Erk1/2 inhibitor PD98059 prior to the adhesion assay on collagen IV. 
As shown in Figure 2A, PD98059 blocked the matrix adhesion of NCAM-Fc-treated cells, 
implicating Erk1/2 as key mediators of NCAM-induced cell adhesion. Interestingly, also the 
adhesion stimulated by FGF-1 required Erk1/2 activity (Figure 2A), which supports the 
hypothesis that NCAM and FGF elicit common signaling pathways. Very similar results were 
obtained in L cells stimulated with NCAM-Fc or FGF-2, where matrix adhesion was 
repressed in the presence of PD98059 (Figure 2B). Based on these data, we verified whether 
soluble NCAM-Fc stimulates Erk1/2 activation. In agreement with our previous result 
(Cavallaro et al., 2001), NCAM-expressing β tumor cells exhibited constitutive activation of 
Erk1/2, which was not enhanced by the treatment with NCAM-Fc (Figure  2C).  
 
 
Figure 2, A and B: NCAM signaling is mediated by Erk1/2 
 NCAM-/- β tumor cells (A) or L cells (B) were stimulated for 10 minutes with NCAM-Fc, FGF-1 or 
FGF-2. Prior to stimulation, cells where pre-incubated with PD98059 (grey bars) or DMSO alone 
(white bars) for 30 minutes. After treatment, cells were subjected to adhesion assays on collagen IV-
coated wells. Adherent cells were counted and are indicated as percentage of control, untreated cells ± 









Figure 2C: Constitutive activation of β 
tumor cells 
NCAM+/+ β tumor cells were stimulated 
for 10 or 30 minutes with NCAM-Fc, 
DFN2-Fc, or FGL. Cells were then lysed 
and immunoblotted for phospho-Erk1/2, 
followed by stripping and immnoblotting 
for total Erk1/2. 
 
 
In contrast, NCAM-Fc strongly induced Erk1/2 activation in NCAM-/- β tumor cells, 
an effect that was also recapitulated by the FGL peptide alone, while ∆FN2-Fc was markedly 
less effective (Figure 2D). Once again, the role of NCAM in Erk1/2 activation was not 
restricted to β tumor cells, since we obtained comparable results with fibroblastic L cells. 
Indeed, cells treated with either NCAM-Fc or FGL, but not with ∆FN2-Fc, showed a high 
level of Erk1/2 activation (Figure 2E). This effect was readily inhibited by PD173074 (Figure 
2D), supporting the crucial role of FGFR downstream of NCAM. Besides confirming that the 
membrane insertion is not necessary for certain functions of NCAM, these data imply that the 
direct binding to FGFR is essential for NCAM to stimulate Erk1/2 activation. 
 
Figure 2, D and E: 
(D) NCAM-/- β tumor cells were stimulated for 10 or 30 minutes with NCAM-Fc, ∆FN2-Fc, or FGL. 
Cell lysates were then immunoblotted for phospho-Erk1/2 (top panel), followed by stripping and 
immunoblotting for total Erk1/2 (bottom panel). The densitometric ratio between phosphorylated and 
total Erk1/2 was measured for each time point, and the induction of Erk activation relative to untreated 
cells (time 0) is indicated as arbitrary units.  (E) L cells were stimulated for 10 minutes with NCAM-
Fc, ∆FN2-Fc, FGL, or FGF-2. Cells where pre-incubated for 2 hours with PD173074 prior to the 
stimulus as indicated. Cells were then lysed and immunoblotted for phospho-Erk1/2 (top panel), 
followed by stripping and immunoblotting for total Erk1/2 (bottom panel). The densitometric ratio 
between phosphorylated and total Erk1/2 was measured for each treatment, and the induction of Erk 
activation relative to untreated cells is presented as arbitrary units. 
 
3. NCAM acts as a molecular switch for FGFR signaling 
 
 50
3.3.3. NCAM and FGF activate distinct, FGFR-mediated signaling pathways 
 
We have previously reported that NCAM induces both cell-matrix adhesion and 
neurite outgrowth in β tumor cells in an FGFR-dependent manner (Cavallaro et al., 2001). 
However, only cell-matrix adhesion and not neurite outgrowth could be rescued in NCAM-
deficient cells treated with FGF, implying that the interaction of NCAM with FGFR induces a 
downstream signaling that is distinct, although partially overlapping, from that of FGF. Based 
on the observation that NCAM-induced Erk1/2 activation was inhibited by the broad-
spectrum PKC inhibitor calphostin-C in both β tumor cells and L cells (Figure 3A and B), we 
investigated NCAM- and FGF-mediated differences in protein kinase C (PKC) signaling. The 
biological significance of NCAM-induced PKC activation was underscored by the 
observation that the PKC activator phorbol 12-myristate 13-acetate (PMA) induced both 
Erk1/2 activation (not shown) and adhesion of NCAM-/- β tumor cells to collagen IV (Figure 
3C). However, calphostin-C also repressed the Erk1/2 activation induced by FGF-1 in β 
tumor cells and FGF-2 in L cells (Figure 3A and B), indicating that both NCAM and FGF 
signal via PKC. Nevertheless, given that several PKC family members with distinct functions 
and partners are normally co-expressed in most cell types (Jaken and Parker, 2000), the 
activation of different PKC isoenzymes may account for the differential FGFR-mediated 
signaling stimulated by NCAM and FGF. To test this hypothesis, we first set out to identify 
the PKC acting downstream of NCAM. Since PKCβII has been previously implicated in 
NCAM signaling in neurons (Leshchyns'ka et al., 2003), we verified whether this applied also 
to our cellular systems. Indeed, immunoblotting analyses on L cell lysates with an antibody 
against activated PKCβII revealed that NCAM-Fc induces the activation of PKCβII. Notably, 
this effect was inhibited by PD173074 (Figure 4A), indicating that NCAM-Fc-induced 
activation of PKCβII requires FGFR signaling. Based on the implication of PKCβII in NCAM 
signaling, we assessed whether the two molecules are physically associated. Co-
immunoprecipitation analysis on NCAM-positive β tumor cells showed that NCAM 
associated with PKCβII, but not with PKCα, which is also expressed by these cells (Figure 
4B, left). The formation of a NCAM/PKCβII complex was also confirmed in L cells upon 
transfection with NCAM (Figure 4B, right), indicating that it is not a phenomenon restricted 
to β tumor cells. In contrast to NCAM-Fc, FGF failed to promote PKCβII activation (Figure 
4A), supporting the hypothesis of a dichotomy in the FGFR-mediated signaling pathways 















Figure 3:PKC stimulates Erk1/2 and adhesion 
 (A and B) NCAM-/- β tumor cells (A) or L cells (B) were stimulated for 10 minutes with NCAM-Fc, 
FGF-1 or FGF-2. When needed, cells were pre-incubated with 400 nM Calphostin C for 30 minutes. 
Cells were then lysed and immunoblotted for phospho-Erk1/2, followed by stripping and 
immunoblotting for total Erk1/2. (C) NCAM-/- β tumor cells were treated with the indicated 
concentrations of PMA or arachidonic acid for 1 hour, followed by adhesion assays on collagen IV-
coated wells. Adherent cells were counted, and the results presented as percentage of control, 










Figure 4. NCAM-activates PKCβII in an FGFR-dependent manner 
 (A) L cells were stimulated for 10 minutes with NCAM-Fc or FGF-2, with or without a pre-treatment 
with PD173074 for 2 hours. Cells were then lysed and immunoblotted for phospho-PKCβII (top panel), 
followed by stripping and immunoblotting for total PKCβII (bottom panel). (B) PKC isoforms were 
immunoprecipitated from protein extracts of NCAM+/+ β tumor cells (left panels) or of mock- or 
NCAM-transfected L cells (right panels). Immunoprecipitates were then probed with antibodies 
against NCAM or against the specific PKC isoforms as indicated. 
 
 
To gain further insight into the biological relevance of NCAM-induced PKCβII 
activation, we took advantage of CGP53353, a chemical compound that selectively inhibits 
PKCβII function (Kouroedov et al., 2004). CGP53353 was used to investigate the role of 
PKCβII in NCAM-induced cell adhesion. As shown in Figure 5A and B, CGP53353 repressed 
cell-matrix adhesion of both NCAM-/- β tumor cells and L cells stimulated with NCAM-Fc, 
supporting the role of PKCβII as an effector of NCAM signaling. In contrast, CGP53353 
showed no effect on FGF-induced cell-matrix adhesion (Figure 5A and B), confirming that 
PKCβII is not involved in the signaling cascade elicited by FGF. Rather, FGF appeared to 
induce the activation of PKCα and/or γ, since the compound HBDEE, which selectively 
inhibits PKCα and γ (Kashiwada et al., 1994), blocked the matrix adhesion of L cells 
stimulated with FGF-2, but not with NCAM-Fc (Figure 5C).  A similar picture emerged when 
we analyzed the Erk1/2 activation pathways in both NCAM-/- β tumor cells and L cells: 
while CGP53353 inhibited the phosphorylation of Erk1/2 in cells treated with NCAM-Fc, but 
not with FGF, HBDEE showed the opposite effect (Figure 5D). Finally, in agreement with 
previous reports on the brain-restricted expression of PKCγ (Musashi et al., 2000), we did not 
detect this PKC isoenzyme in our cellular systems (not shown), indicating that in the 
experiments described above HBDEE acted as a selective PKCα inhibitor. Taken together, 
these results indicate that NCAM activates PKCβII in an FGFR-dependent manner whereas 
FGF activates PKCα, strongly supporting the notion that the two molecules induce distinct 
signaling cascades. 
 





Figure 5: NCAM and FGF activate different PKC isoenzymes.  
(A) NCAM-/- β tumor cells were stimulated for 10 minutes with NCAM-Fc or FGF-1, in the absence 
(white bars) or presence of CGP53353 (grey bars). Cells were then subjected to adhesion assays on 
collagen IV. Adherent cells were counted and the results are presented as percentage of control, 
untreated cells ± SD. Experiments were performed in quadruplicate. *p<0.005. (B and C) L cells were 
stimulated for 10 minutes with NCAM-Fc or FGF-2, in the absence (white bars) or presence (grey 
bars) of 10 µM CGP53353  (B) or 100 µM HBDEE (C). Cells were then subjected to adhesion assays 
on collagen IV. Adherent cells were counted and are indicated as percentage of control, untreated cells 
± SD. Experiments were performed in quadruplicate. *p<0.005. (D) NCAM-/- β tumor cells (left panel) 
were stimulated for 10 minutes with NCAM-Fc or FGF-1, with or without a pre-treatment with 
CGP53353. L cells (middle and right panels) were stimulated for 10 minutes with either 20 µg/ml 
NCAM-Fc or 20 ng/ml FGF-2, with or without a pre-treatment with 10 µM CGP53353 (middle panel) 
or 100 µM HBDEE (right panel), as indicated. Treated cells were lysed and immunoblotted for 
phospho-Erk1/2, followed by stripping and immunoblotting for total Erk1/2. 
 
 
To gain further insight into the dichotomy in the FGFR signaling activated by NCAM 
and FGF, we focused on additional candidate effectors. Our previous results indicated that 
non-receptor tyrosine kinases of the Src family associate with the NCAM/FGFR complex in β 
tumor cells. Moreover the inhibition of Src kinases with the compound PP1 resulted in the 
neutralization of NCAM function (Cavallaro et al., 2001), thus implicating Src in the 
signaling elicited by the NCAM/FGFR complex. This hypothesis has been confirmed 
biochemically, based on the observation that treating NCAM-negative L cells with NCAM-Fc 
induced Src activation, as revealed by the use of an antibody that specifically recognizes the 
active form of the kinase (Figure 6A). The antibodies that were used in these experiments 
cross-reacted with various members of the Src family, excluding a clear distinction between 
the specific Src family kinase(s) activated by NCAM. NCAM-Fc-induced activation of Src 
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kinases was mediated by FGFR, since it was abolished by PD174074 (Figure 6A). Moreover, 
as shown in Figure 6B, PP1 inhibited the activation of Erk1/2 in cells treated with NCAM-Fc, 
implicating Src kinases as signaling effectors of the NCAM/FGFR complex upstream of 
Erk1/2. Notably, when cells were treated with FGF-2, no Src activation was detected (Figure 
6A). In agreement with this, the Src inhibitor PP1 showed no effect on FGF-induced 
activation of Erk1/2 (Figure 6B). Therefore, NCAM induced Src activation in an FGFR-
dependent, whereas FGF was unable to regulate Src activity. We have also focused on 
another classical target of FGFR signaling, namely FGF-receptor substrate-2 (FRS2) that is 
known to undergo tyrosine phosphorylation upon activation of FGFR (Eswarakumar et al., 
2005). Unlike PKCβII and Src, both NCAM-Fc and FGF-2 were able to induce FRS2 
phosphorylation in L cells, as demonstrated by immunoblotting the lysates of stimulated cells 
with an antibody against phospho-FRS2 (Figure 6C). Finally, PD173074 abolished FRS2 
phosphorylation in cells stimulated either with NCAM-Fc or with FGF-2, confirming the 
involvement of FGFR in the signaling elicited by both proteins. 
Taken together, these results support the notion that both NCAM and FGF induce 
FGFR activation, yet the receptor responses and the downstream signaling pathways evoked 







Figure 6: NCAM and FGF activate distinct, 
FGFR-mediated signaling pathways 
 L cells were stimulated for 10 minutes with 
NCAM-Fc or FGF-2, with or without a pre-
treatment with PD173074 for 2 hours (A and C) 
or with PP1 for 30 minutes (B). Cells were then 
lysed and immunoblotted for phospho-Src (A, top 
panel), phospho-Erk1/2 (B, top panel) or 
phospho-FRS2 (C, top panel), followed by 
stripping and immunoblotting for total Src, 
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3.3.4. NCAM regulates the cellular response to FGF 
 
Since both NCAM and FGF stimulate FGFR signaling, we next assessed whether 
NCAM modulates the cellular response to FGF. Although NCAM per se stimulated cell-
matrix adhesion (Cavallaro et al., 2001; Figures 1 and 7A), it strongly inhibited the adhesion 
induced by FGF. Moreover, serum-induced adhesion was also repressed upon expression of 
NCAM (Figure 7A). Finally, NCAM-Fc also slightly represses the adhesion of NCAM-
transfected cells (Figure 7A), suggesting that NCAM homophilic interactions do not account 
for NCAM-dependent cell-matrix adhesion.  
We have previously reported that FGF induces MAPK activation in NCAM-/- β 
tumor cells, whereas wild-type cells, which exhibited a constitutive activation of the MAPK 
pathway, did not further respond to FGF treatment (Cavallaro et al., 2001), suggesting that 
NCAM may interfere with FGF function. However, those results were obtained on cell lines 
derived from tumors of different animals, raising the possibility that the different responses to 
FGF were due to intrinsic differences between the two cell lines, rather than to the expression 
of NCAM. Hence, we performed these experiments on mock- vs. NCAM-transfected L cells. 
Serum-starved L-mock cells showed a very low level of basal activation of Erk1/2, which was 
strongly enhanced by FGF-2. In contrast, the forced expression of NCAM resulted in 
constitutive MAPK activation that was only slightly increased by FGF-2 (Figure 7B, upper 
panel). This differential response to FGF-2 by L-mock and L-NCAM cells recapitulated that 
of NCAM-/- vs. wild-type β tumor cells (Cavallaro et al., 2001). Furthermore, in time-course 
experiments L-mock cells exhibited a strong and sustained response to FGF-2 for at least 4 
hours, while the small peak of Erk1/2 activation in L-NCAM cells declined rapidly to the 
basal level (Figure 7B, bottom panel). Since MAPK activation often represents a proliferative 
signal, we verified whether NCAM affected the proliferation of L cells. Indeed, while L cells 
showed a strong proliferative response to recombinant FGF-2, this effect was markedly 
inhibited by the expression of NCAM (Figure 7C). A similar inhibitory effect was observed 
when cells were stimulated with fetal bovine serum. Thus, NCAM exerts a negative 
regulation on FGF-induced cell adhesion, MAPK activation and cell proliferation, supporting 
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Figure 7: NCAM regulates the cellular 
response to FGF 
(A) Mock (open bars) or NCAM-transfected 
L cells (solid bars) were stimulated for 10 
minutes with either 10% fetal calf serum, 20 
ng/ml FGF-2, or 20 µg/ml NCAM-Fc, 
followed by adhesion assays on collagen IV-
coated wells. Adherent cells were counted 
and the results are presented as percentage 
of control, untreated L-mock cells ± standard 
deviation. Experiments were performed in 
triplicate. *p<0.005. (B) Upper panel: mock- 
or NCAM-transfected L cells were stimulated 
for 10 minutes with FGF-2, followed by cell 
lysis and immunoblotting for phospho-Erk1/2 
and then for total Erk1/2. Bottom panel:  
mock- (solid squares) or NCAM-transfected 
L cells (solid triangles) were treated with 20 
ng/ml FGF-2 for the indicated time lengths. 
After the treatment cells were lysed and 
subjected to SDS-PAGE and immunoblotting 
for phospho-Erk1/2, followed by stripping 
and immunoblotting for total Erk1/2. The 
densitometric ratio between phosphorylated 
and total Erk1/2 was measured for each time 
point. The values relative to the basal 
activation of Erk1/2 (time 0) in a 
representative experiment are shown. The 
experiment was repeated three times with 
similar results. (C) Mock- (open symbols) or 
NCAM-transfected L cells (solid symbols) 
were treated daily with 10% fetal calf serum 
(triangles) or 20 ng/ml FGF-2 (circles) for 4 
days. Cells were counted every 24 hours and 
the ratio with non-stimulated L-mock cells 
was determined for each time point. 
Experiment were performed in quadruplicate 
± SD. *p<0.005 (L-NCAM vs. L-mock). 
 





While NCAM has long been known to control various functions in the nervous 
systems, which include progenitor cell migration, axon guidance, mossy fiber fasciculation 
and spatial learning (Hinsby et al., 2004), its role in non-neuronal tissue has remained elusive. 
We have previously shown that the loss of NCAM in pancreatic β cell tumors results in tissue 
disaggregation and lymph node metastasis (Cavallaro et al., 2001). The latter event is likely 
due to the tumor-associated lymphangiogenesis caused by NCAM deficiency (Crnic et al., 
2004). Tissue disaggregation and tumor cell detachment reflect a deficit in β1-integrin-
mediated cell-matrix adhesion. Indeed, we have previously reported that NCAM stimulates 
the activation of β1-integrin and, hence, matrix adhesion by triggering a signaling cascade 
mediated by FGFR. These observations led us to the identification of a novel signaling 
complex in which NCAM associates with FGFR and with N-cadherin (Cavallaro et al., 2001). 
Strong support for this model came from protein-protein interaction studies that revealed the 
direct binding of NCAM to FGFR, with the interaction domains mapping in the two 
membrane-proximal F3 repeats of NCAM and in the second and third Ig loops of FGFR 
(Kiselyov et al., 2003). Thus, given that NCAM homophilic interactions are mediated by the 
membrane-distal Ig1-2-3 domains (Soroka et al., 2003), one should be able to investigate the 
NCAM/FGFR cross-talk independently from the cell-cell adhesive properties of NCAM. In 
this study, we show that the binding of NCAM to FGFR and an intact FGFR signaling are 
essential for the stimulation of specific events such as Erk1/2 activation and cell-matrix 
adhesion. An interplay between adhesion molecules, including NCAM, and FGFR has long 
been proposed in the nervous system (Walsh and Doherty, 1997). We provide further 
experimental support for this model by showing that NCAM acts as a direct inducer of FGFR 
function in non-neuronal cells. Based on our results with soluble NCAM-Fc, the membrane 
localization of NCAM is dispensable for its interaction with FGFR. NCAM shedding has 
been described in cultured cells (Deak et al., 2005; Diestel et al., in press), and soluble forms 
of NCAM have been detected in human cerebrospinal fluid and serum, with high levels in 
severe neurological disorders and in cancer patients (Gower et al., 1988;  Ledermann et al., 
1994;  Lynch et al., 1997; Torado et al., 2004). Moreover, the production of soluble NCAM in 
mice lacking membrane-associated NCAM results in embryonic lethality (Rabinowitz et al., 
1996), thus highlighting the biological relevance of NCAM’s heterophilic interactions. In this 
context, our data point to FGFR as a major effector of soluble NCAM, raising the intriguing 
hypothesis that NCAM acts as a bone fide ligand for FGFR in vivo. Such a novel ligand-
receptor interaction needs further investigation, in particular to verify whether it plays a 
pathogenetic role in diseases characterized by excessive release of soluble NCAM, potentially 
resulting in aberrant activation of FGFR and/or the inhibition of FGF-induced FGFR 
signaling. 
An interesting implication of our data is that, although both NCAM and FGF 
stimulate FGFR activity, only a subset of FGFR-dependent events is elicited by both 
molecules. Indeed, while NCAM induces neurite outgrowth in β tumor cells by binding to 
and activating FGFR, FGF is unable to rescue this process in NCAM-deficient cells 
(Cavallaro et al., 2001). In contrast, both NCAM and FGF stimulate FGFR-mediated matrix 
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adhesion and Erk1/2 activation in NCAM-/- tumor β cells and in L cells. Finally, FGF exerts 
a proliferative effect that is not recapitulated by NCAM, either membrane-associated 
(Cavallaro et al., 2001) or as a soluble molecule (our unpublished data). To gain insights into 
the molecular mechanisms that account for this dichotomy between NCAM and FGF-induced 
FGFR signaling, we have dissected the biochemical cascades elicited by the two molecules. 
Both NCAM and FGF induce the activation of two classical FGFR substrates, namely PLCγ 
and FRS2. However, the signaling pathways elicited by NCAM and FGF were clearly 
divergent at the level of PKC, in that NCAM induced PKCβII whereas FGF stimulated PKCα. 
The activation of PKCβII was not due to NCAM homophilic interactions, since it was induced 
by stimulating NCAM-negative cells (either β tumor cells or fibroblastic cells) with soluble 
NCAM-Fc. Moreover, the inhibition of FGFR signaling repressed NCAM-induced PKCβII 
activation, clearly indicating that it is mediated by FGFR, as previously shown in neurons 
(Leshchyns'ka et al., 2003). The induction of PKC occurs also upon NCAM homophilic 
binding, i.e. during NCAM-mediated cell-cell adhesion and neurite outgrowth. However, in 
that case NCAM activates multiple PKC isoenzymes, including PKCα (Kolkova et al., 2005). 
Hence, NCAM-NCAM and NCAM-FGFR interactions elicit different signaling pathways, as 
it was recently proposed by Kiryushko and co-workers (Kiryushko et al., 2006). In that study, 
however, NCAM-induced activation of Src kinases appeared to be independent of FGFR, 
while we have clearly shown that FGFR signaling is required downstream of NCAM in order 
to stimulate Src activation. Such a discrepancy might be due to the cell type-specificity of 
NCAM functions, given that Kiryushko and co-workers analysed NCAM signaling in 
neurons, while our studies were performed in non-neuronal cells. Our data on the divergent 
FGFR signaling pathways downstream of NCAM and FGF are also supported by the 
observation that the adaptor protein ShcA is phosphorylated in an FGFR-dependent manner 
upon NCAM-induced neurite outgrowth, but not following FGF stimulation (Hinsby et al., 
2004). 
Hence, NCAM and FGF induce FGFR signaling in a different manner, and future 
work should address the molecular basis of this divergence. For example, it would be 
insightful to elucidate whether NCAM, especially when associated to the membrane, induces 
the clustering of FGFR, a property that would not be shared with FGF. Indeed, lateral 
clustering of NCAM has been described and involves the first three Ig domains (Soroka et al., 
2003). Thus, the integration of NCAM cis-oligomerization with FGFR binding would appear 
as a novel mechanism of FGFR activation. Alternatively, NCAM, unlike FGF, might recruit 
FGFR to specific cell surface compartments, implying that the divergence between NCAM 
and FGF signaling is dictated by spatial parameters that are also fulfilled by soluble NCAM-
Fc.  
Our studies demonstrate that NCAM not only directly stimulates FGFR activity, but 
also exerts a regulatory function on the cellular response to FGF. Indeed, we have provided 
experimental evidence that various FGF-induced effects, including matrix adhesion, MAPK 
activation and cell proliferation, are repressed upon concomitant expression of NCAM. An 
inhibitory effect of NCAM on FGF-stimulated cell proliferation has been described in 
astrocytes and in neural progenitor cells. In the first case, it was attributed to NCAM’s 
homophilic interactions (Krushel et al., 1998), whereas heterophilic partners were implicated 
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in the anti-proliferative function of NCAM in neural progenitors (Amoureux et al., 2000). 
Based on the data presented here, we propose that NCAM exerts a tight control on the cellular 
response to FGF, which not only extends beyond the central nervous system (we observed it 
in pancreatic β cells and in fibroblasts), but is also not restricted to the control of cell 
proliferation, in that it also modulates cell-matrix adhesion (see Figure 7A). FGFs induce a 
wide variety of cellular processes that depend on a complex network of signaling and 
transcriptional events that is cell type-specific. Notably, the control mechanisms that have 
been invoked so far to explain the differential responses to FGFs are mostly intracellular 
(Dailey et al., 2005). Our data implicate membrane-associated NCAM as a novel and 
important regulator of FGF signaling, adding a further level of modulation of FGFR activity.  
The aberrant expression and/or function of NCAM have been described in several 
pathological conditions, ranging form neurological to neoplastic diseases (Vawter, 2000; 
Mikkonen et al., 2001; Cavallaro and Christofori, 2004). In addition, NCAM-/- mice exhibit 
significant developmental and behavioral defects (Cremer et al., 1994; Cremer et al., 1997; 
Stork et al., 1997; Stork et al., 1999). The pathogenetic role of NCAM in these disorders has 
been attributed to the dysregulation of its adhesive properties. However, based on the data 
presented here, aberrant FGFR function needs to be considered as an additional consequence 
of NCAM alterations, and investigated as a possible pathogenetic factor. For example, 
excessive FGFR signaling in tumors induces cancer cell proliferation, survival and invasion, 
together with angiogenesis and metastasis (Grose and Dickson, 2005). Together with the 
notion that NCAM expression is reduced during the progression of certain tumor types 
(Cavallaro and Christofori, 2004) and that its loss induces metastasis (Perl et al., 1999), this 
implies that NCAM might act as a tumor suppressor by negatively regulating FGFR 
signaling. Indeed, NCAM-dependent inhibition of FGFR activity has been observed not only 
in β tumor cells (Cavallaro et al., 2001), but also in other cancer cell types (S. Zecchini, A. 
Godwin, M. Bianchi, P, Nuciforo, and U. Cavallaro, manuscript in preparation). 
In summary, we have shown that NCAM can act as an activating ligand for FGFR 
and as a modulator of the cellular response to FGF stimulation. Future studies should address 
the molecular basis of these additional functions of NCAM, thus unraveling a novel 
mechanism for the regulation of FGFR activity and hopefully leading to innovative 
therapeutic approaches for those diseases caused by dysfunction of NCAM and/or FGFR. 
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Neural cell adhesion molecule (NCAM) has been mainly studied in the central 
nervous system where it mediates processes, such as neurite outgrowth and axon guidance. 
However, NCAMs function in non-neuronal tissues has remained elusive. Using the Rip1Tag 
2 model of multistage tumorigenesis, we have previously reported that loss of NCAM induces 
tissue disaggregation, lymphangiogenesis and metastasis. These processes might result from 
the loss of FGFR signaling–dependent activation of β1-integrin in NCAM-deficient cells. 
Here we show that interference with β1-integrin function in the Rip1Tag2 model leads do 
tumor cell cluster dissemination into lymphatics but not to increased lymphangiongenesis. 
Moreover, β1-integrin-deficient cells are not able to metastasize, and tumors with reduced β1-
integrin expression are smaller, probably due to the induction of senescence. Our results 
indicate a so far unknown role of β1-integrin in senescence. 
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 The Neural Cell Adhesion Molecule NCAM is a member of the family of Ca2+-
independent cell adhesion molecules, mediating homotypic cell-cell as well as heterotypic 
cell-matrix adhesion (Cunningham, 1995; Rutishauser, 1993).  NCAM is expressed during 
development and its involvement in developmental processes has been studied in great detail 
(Walsh and Doherty, 1997). In the adult, NCAM expression is mainly found in neuronal 
tissues but also in skeletal muscle cells (Dickson et al., 1987) as well as some neuroendocrine 
tissues such as pancreas (Rouiller et al., 1990; Langley et al., 1989; Cirulli et al., 1994). In 
many human cancers, NCAM expression changes from the adult, 120kD GPI-anchored 
isoform to the embryonic, 140kD and 180kD transmembrane isoforms (Johnson, 1991; Kaiser 
et al., 1996; Lipinski et al., 1987; Moolenaar et al., 1992; Roth et al., 1988). Furthermore, 
reduced overall expression of NCAM has been correlated with poor prognosis in 
astrocytomas, colon and pancreatic cancer (Fogar et al., 1997; Huerta et al., 2001; Sasaki et 
al., 1998). Besides its function as a cell-cell adhesion molecule, recent research has focused 
on NCAMs role in signal transduction (reviewed in Walmod et al., 2004). 
We have previously employed a transgenic mouse model of β cell carcinogenesis 
(Rip1Tag2; Hanahan, 1985) to study NCAM function during tumor progression. In Rip1Tag2 
mice (RT2 mice), the Simian Virus large T oncogene is expressed under the control of the Rat 
insulin promoter, resulting in the reproducible development of β cell tumors following a 
multistage tumorigenesis pathway. These mice usually do not form metastases. However, 
when crossed to NCAM knock-out mice (NCAM-/- mice), formation of metastasis could be 
observed in 50% of the resulting RT2;NCAM-/- mice (Perl et al., 1999). Further 
investigations revealed that in NCAM-deficient tumors, tumor-associated lymphangiogenesis 
is induced via de novo-expression of the lymphangiogenic factors VEGF-C and VEGF-D. 
Repression of VEGF-C and VEGF-D function by adenoviral expression of a soluble form of 
their cognate receptor (VEGFR-3) resulted in reduced metastasis formation in RT2;NCAM-/- 
mice, suggesting that loss of NCAM promotes metastasis by induction of lymphangiogenesis 
(Crnic et al., 2004).  
Another feature of NCAM-/- tumors is the occurrence of alterations in tissue 
architecture, namely tumor tissue disaggregation and the appearance of hemorrhagic cavities. 
Clusters of tumor cells are found floating in these lacunae. Cell lines derived from NCAM 
expressing RT2 tumors (βT2 cells) and NCAM-deficient RT2;NCAM-/- tumors  (βTN2 cells) 
revealed that NCAM deficiency leads to impaired cell-matrix adhesion but does not alter cell-
cell adhesive properties in vitro. Extensive biochemical analysis identified a potential 
mechanism by which NCAM could affect cell-matrix adhesion. In βT2 cells, NCAM 
associates and activates FGFR-4, leading to the assembly of a classical signaling complex. 
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The activation results, via as yet unidentified pathway(s), in the stimulation of β1-integrin 
dependent adhesion to ECM proteins such as collagen IV (Cavallaro et al., 2001).  
β1-integrin belongs to the family of integrin transmembrane receptors consisting of   
8 β and 18 α subunits that assemble as heterodimers to form 24 distinct integrins. The main 
ligands for integrins are extracellular matrix proteins and cellular counter-receptors. In their 
role as the major adhesion receptors, integrins signal across the plasma membrane in both 
directions: high affinity ligand binding requires integrins to become activated by undergoing 
conformational changes regulated by inside-out signals. In turn, integrin ligation triggers 
outside-in signals that regulate different aspects of cell behavior such as cell survival, control 
of transcription, cell proliferation, cell motility and cytoskeletal organization (Hynes, 2002). 
Due to their broad spectrum of features, integrins and integrin signaling have been shown to 
contribute to tumor progression in various ways (Guo and Giancotti, 2004). Recent reports 
have shown that β1-integrin expression is critical for the initiation of mammary tumorigenesis 
in vivo, and for maintaining the proliferative capacity of late stage tumor cells .  
Our aim was to investigate the role of β1-integrin in inducing the phenotypes 
observed in RT2;NCAM-/- mice, namely tissue disaggregation and increased 
lymphangiogenesis. To address this question, we employed the RT2 tumor mouse model 
carrying a conditional, β cell specific knock-out of the β1-integrin locus. We show that a 
partial deletion of β1-integrin in β cell tumorigenesis leads to tumor cluster dissemination into 
lymphatics but does not induce lymphangiogenesis and metastasis. Mice having lost β1-
integrin expression in β cells display reduced tumor burden, most likely through the induction 
of senescence.  Furthermore, tumor cells lacking β1-integrin are not able to form tumors and 
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4.2. Materials and Methods 
 
 
4.2.1. Histopathological analysis 
 
The following antibodies were used for immunohistochemistry or 
immunofluorescence on paraffin sections: guinea pig anti-insulin (DakoCytomation, 
Glostrup, Denmark), rabbit anti-mouse LYVE-1 (Reliatech, Braunschweig, Germany), 
biotinylated mouse anti-BrdU (Zymed, South San Francisco, CA) for detection of 
proliferating cells, In Situ Cell Death Detection Kit, (TUNEL, Roche, Basel, Switzerland) for 
visualization of apoptotic cells. All biotinylated secondary antibodies for 
immunohistochemistry (Vector, Burlingame, CA) were used at a 1:200 dilution, and positive 
staining was visualized with the ABC horseradish peroxidase kit (Vector) and DAB 
Peroxidase Substrate (Sigma Chemical Co., St. Louis, MO) according to the manufacturer’s 
recommendations. For analysis of tissue morphology, slides were slightly counterstained with 
hematoxylin or eosin. Alexa Fluor 568- and 488-labeled secondary antibodies (Molecular 
Probes, Eugene, OR) diluted 1:400 were used for immunofluorescence analysis.  
6-Diamidino-2-phenylindole (DAPI) was used for nuclear staining in immunofluorescence 
stainings. All paraffin-embedded sections were subject to antigen retrieval with 10 mM citrate 
buffer (microwave) except for insulin and glucagon (10 min in 0.2% Triton X-100 in PBS), 
BrdU (1 h in 2N HCl and subsequently 1 h 1x trypsin at room temperature), and TUNEL  
(10 min 2 µg/ml Proteinase K (Fluka) at room temperature). Stained sections were viewed on 
a Axioskop 2 plus light microsope (Zeiss, Feldbach, Switzerland) using the axiovision  
3.1. software (Zeiss, Feldbach, Switzerland) or a Nikon Diaphot 300 immunofluorescence 
microscope (Nikon, Egg, Switzerland) using the Openlab 3.1.7. software (Improvision, 
Coventry, England). 
For BrdU labeling, 100 µg BrdU (Sigma Chemical Co., St. Louis, MO) per gram 
body weight were injected 90 min before sacrificing the mice. To determine tumor cell 
proliferation/apoptotic indices, BrdU-/TUNEL-positive nuclei were counted per randomly 
chosen 40x magnification field of tumor tissue, respectively. Approximately 10 fields/mouse 
were counted.  
Lymphangiogenesis was quantified by assessing the extent by which LYVE-1-
positive lymphatic vessels surrounded the tumor perimeter. Tumors from all mice of a 
genotype were grouped into five classes: tumors that were not in contact with any lymphatic 
vessel (0%), tumors that were surrounded less than 10% (< 10%), less that 25% (< 25%), less 
than 50% (< 50%), and tumors that were surrounded more than 50% of the tumor perimeter 
by lymphatics (> 50%).  
Tumor grading: Tumors were categorized into following sub-classes: 
normal/hyperplastic islet (including normal as well as enlarged islets), adenoma (larger than  
1 mm in diameter, well differentiated tumor cells, encapsulated tumor, no invasive tumor 
edges), carcinoma grade 1 (well differentiated, one invasive tumor edge), carcinoma grade  
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2 (partially dedifferentiated, tumor capsule largely absent, more than one invasive tumor 
edge), carcinoma grade 3 or anaplastic tumor (complete loss of tumor cell differentiation).  
 
The islet area was measured on pictures of insulin and glucagon stained slides using 
the ImageJ software of the National Institutes of Health (http://rsb.info.nih.gov/ij/). All 
statistical analyses were performed using the GraphPad software. 
 
 
4.2.2. Mouse tissue processing 
 
Animal care was in accordance with Swiss Animal Protection Ordinance issued by 
the Swiss Federal Veterinary Office. All mice were sacrificed between 12 and 13 weeks of 
age. Tumor incidence per mouse was determined by counting all macroscopically apparent 
tumors with a minimal diameter of 1 mm. Tumor volume was defined as total tumor volume 
per mouse in mm3, calculated by measuring the tumor diameters assuming a spherical or 
elliptical shape of the tumors. Tumors and pancreata were fixed overnight in 4% 
paraformaldehyde in PBS, dehydrated in a Microm Spin Tissue Processor STP-120 (Microm, 
Volketswil, Switzerland) and paraffin-embedded. 5 µm paraffin-embedded tissue sections 
were deparaffinized and re-hydrated prior to usage according to standard procedures. 
 
 
4.2.3. Tissue culture 
 
All cell lines were grown in DMEM supplemented with 10% fetal bovine serum,  
2 mmol/L glutamine and 100 units/mL penicillin. Tumor cell lines were established from 
insulinomas of twelve week-old RT2;β1fl/fl and RCre;RT2;β1fl/fl mice as described in 
(Cavallaro et al., 2001). In brief, tumors were excised from pancreata and single-cell 
suspended in cold PBS. The suspension was mixed 1:1 with DMEM supplemented with 10% 
fetal bovine serum, 10 % horse serum, 2 mmol/L glutamine and 100 units/mL penicillin. 
After 1 minute of sedimentation at room temperature, the supernatant was transferred to a 
new tube, re-mixed 1:1 with medium and let sediment another 10 min at room temperature. 
The pellet containing the tumor cells was resuspended and cells were plated on 24-well plates 
for further expansion. For transplantation of tumor cells, 106 cells in PBS were injected 
subcutaneously into the two flanks of C57 mice, or intravenously into athymic nude mice 
anesthetized with isoflurane (Minrad Inc., Buffalo, NY). 
 
 
4.2.4. Cell adhesion  
 
Matrix adhesion assays were performed on collagen IV, a substrate that mediates 
NCAM-dependent cell adhesion (Cavallaro et al., 2001). 96-well plates were coated with  
5 µg/cm2 of mouse collagen IV (BD Biosciences).  6x104 cells were seeded per well, after  
4. β1-integrin deletion induces tumor cell 
dissemination and reduction of tumor burden 
 
 65
90 minutes, non adherent cells were removed by washing with PBS. Adherent cells were 
fixed for 20 minutes with 25% glutaraldehyde (Sigma), stained with crystal violet, washed 
and air-dried. Bound dye was solubilized with 10 % acetic acid and absorbance measured at 
595 nm. Cell-free wells served as blanks. The assays were performed in triplicates. 
 
 
4.2.5. Cell proliferation 
 
105 cells were seeded onto 24 well plates at t = 0 hours. About every 24 hours, 100 µl 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5mg/ml in PBS) was 
added to the investigated well.  After incubation for 90 minutes at 37 °C, medium was 
removed and 500 µl solubilization buffer (95% isopropanol, 5% formic acid) was added and 
incubated for 5 minutes at RT. Absorption of the solution was determined at 570 nm. 
 For growth in 3D culture, 5x104 cells were mixed in matrigel and seeded on a layer of 
solidified matrigel. After solidification of the upper, cell containing matrigel layer, normal 
growth medium was added to the culture.  
 
 
4.2.6. FACS analysis of tumors 
 
Tumors were dissected out of pancreata, put into ice cold PBS and minced into small 
pieces. After washing with PBS, tumor pieces were incubated with a collagenase mix 
(DMEM, 5% NU-serum (Becton Dickinson), 0.16 mg/mL DNase I, 1 mg/mL collagenase D, 
H and collagenase/dispase (Roche), 0.5 mg/mL Collagenase I (Sigma))  to obtain single cell 
suspensions for 30 minutes at 37 °C, followed by filtration and washing with FACS-PBS (1x 
PBS, 2% FCS). Tumor cell suspensions were incubated with anti- β1-integrin-FITC (Serotec) 
and anti-CD31-PE  (Pharmingen) antibodies and analyzed with a FacsScan (Becton 
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4.3. Results  
 
 
4.3.1. β1-integrin is required for islet cell sorting 
 
A complete knock out of the β1-integrin gene results in embryonic lethality. We 
therefore employed mice carrying conditional β1-integrin alleles, β1fl/fl mice, (Fassler and 
Meyer, 1995), and crossed them to mice expressing the Cre recombinase under the control of 
the β cell specific Rat insulin promoter, RipCre, (Ahlgren et al., 1998). This mating gave rise 
to RipCre;β1fl/fl mice that lack β1-integrin specifically in the β cells of the pancreatic islets of 
Langerhans, enabling investigation of its function specifically in this tissue. The effect of β1-
integrin deletion was first looked at with respect to normal islet development. Islets of 
RipCre;β1fl/fl mice were compared to either wild type C57 or β1fl/fl  control mice. In mice, most 
islets adopt their final shape, namely insulin expressing β cells located in the center, and non-
β cells (glucagon expressing α cells, somatostatin producing γ cells and pancreatic 
polypeptide (PP) cells) in the islet periphery, from the age of four to five weeks.  
Histopathological analysis by H&E staining of islets from 8-10 weeks old 
RipCre;β1fl/fl mice showed no apparent changes in islet number, size and architecture  
(Figure 1, upper panel and data not shown). A closer examination by staining pancreata for 
insulin and glucagon, however, revealed differences in the organization of islet cells  
(Figure 1, lower panel). In control animals, most islets (82.4%) displayed a normal 
phenotype, namely α cells located within the three most peripheral cell layers (Figure 1, 
lower left panel). Only in a small percentage of control islets α cells were also found within 
the center of islets (Table1, 17,6%), hereafter referred to as mixed phenotype. In contrast, 
most islets of RipCre;β1fl/fl mice were of the mixed phenotype (81% mixed vs. 19% normal 
phenotype,  Figure 1, lower right panel and Table 1). When calculating the average number of 
α cells per islet area, we found that in RipCre;β1fl/fl islets, total number of  α cells/1000 µm2  
is increased (1.307 α cells/1000 µm2 vs 2.205 α cells/1000 µm2 , Table 1, P<0.005). Thus, 
deletion of β1-integrin leads to disturbances in cell type segregation during islet development. 
 
Figure 1: Sorting phenotype in RipCre;β1fl/fl islets 
Immunohistochemical analysis of wild type (upper 
left) and β1-integrin deleted PFA-fixed sections of 
pancreatic islets by H&E staining show no 
alterations in islet architecture. 
Immunofluorescence co-stainings for insulin 
(green), glucagon (red) and nuclei (DAPI, blue) 
reveal that α cells are not properly located to the 
islet periphery in β1-integrin deficient islets.  
 
 
Table I: Quantification of sorting phenotype  
4. β1-integrin deletion induces tumor cell 




 C57/β1(fl/fl)  RCre;β1(fl/fl) 
N 28  28 
% normal 82,4%  19,0% 
% mixed 17,6%  81% 





*: unpaired t-test 
 
 
4.3.2. Deletion of β1-integrin reduces tumor mass 
 
To investigate the role of β1-integrin in vivo during Rip1Tag2 tumorigenesis, we 
crossed Rip1Tag2 (RT2) mice into the β1fl/fl background, resulting in RT2;β1fl/fl control mice. 
To excise of the β1fl/fl allele specifically in the β cells of the islets of Langerhans, RT2;β1fl/fl 
mice were further crossed to RipCre-mice. Efficient recombination of the β1-integrin gene in 
the resulting RCre;RT2;β1fl/fl experimental and RT2;β1fl/fl control mice was monitored by 
determining β1-integrin protein levels in tumors of 12 weeks old mice. Tumor cells were 
subjected to FACS analysis by performing a CD31 (endothelial cell marker) and β1-integrin 
co-staining, allowing exclusion of endothelial cells from the analysis. More than 95% of the 
cells derived from RT2;β1fl/fl tumors show β1-integrin expression (Region R2 in Figure 2 and 
Table 2), whereas in RCre;RT2;β1fl/fl tumors a second, β1-integrin negative population 
appears (R1). This population represents around 40% of all analyzed cells (Table 2). From 
these experiments, we conclude that the β1fl/fl allele is efficiently recombined in about 40% of 











Figure 2: Histogram of β1-integrin surface levels  
FACS analysis of RT2;β1fl/fl (left panel) and RCre;RT2;β1fl/fl (right panel) tumor cell suspensions 
stained for β1-integrin. Dashed and red lines represent control (unstained) cells and β1-integrin stained 
cells respectively. 
 
Table II: Quantification of β1-integrin surface levels in RT2;β1fl/fl and RCre;RT2;β1fl/fl tumor cell 
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 % of cells in R1 % of cell in R2 
N 3 3 
RT2;β1fl/fl 2,64 +/- 2,08% 96,42 +/- 2.34 
RCre;RT2;β1fl/fl 39,24 +/- 3,07% 56,07 +/- 2,62% 
 
 
The effects of β1-integrin depletion on RipTag2 tumorigenesis were examined by 
immunohistochemical and immunopathological analysis. Control and experimental mice were 
sacrificed at the age of 12 weeks. Tumor-bearing pancreata were excised and tumor incidence 
was scored by counting and measuring macroscopically visible (>1 mm) tumors. Tumor 
incidence (i.e. number of tumors per mouse, Figure 3A) remained unchanged in 
RCre;RT2;β1fl/fl mice as compared to control mice. However, when the total tumor volumes 
were calculated and compared, tumor burden was found to be significantly reduced in 
RCre;RT2;β1fl/fl mice (Figure 3B).  
We next investigated whether the decreased tumor sizes or masses respectively were 
due to a proliferation defect or increased apoptosis in β1-integrin deleted tumors. For this 
purpose, PFA-fixed, paraffin embedded tissue sections of pancreata from 12 weeks old mice 
were prepared followed by immunohistochemical stainings for BrdU (as proliferative marker) 
and TUNEL (marker for cells undergoing apoptosis). RCre;RT2;β1fl/fl tumors were not only 
significantly less proliferative (Figure 3C), but also showed a decreased apoptotic rate  
(Figure 3D). Interestingly, tumor progression was not affected since tumors of both genotypes 
showed a similar incidence of adenomas and grade 1, 2 and 3 carcinomas (Figure 3E). 
4. β1-integrin deletion induces tumor cell 




Figure 3: Statistics of histopathological and histochemical analyses of RT2;β1fl/fl and 
RCre;RT2;β1fl/fl tumors 
Tumor incidences (panel A) and tumor volumes (panel B) of RT2;β1fl/fl control tumors and 
RCre;RT2;β1fl/fl experimental tumors. Proliferating cells were visualized by BrdU staining (panel C) 
and apoptotic cells by the TUNEL reaction (panel D). BrdU or TUNEL positive cells per a defined 
area were counted. For tumor grading (panel E), tumors of H&E stained sections were classified 
according to their histological grading. White bars, RT2;β1fl/fl control tumors; black bars; 
RCre;RT2;β1fl/fl experimental tumors; HYP, hyperplastic islets; AD, adenoma; G1, carcinoma grade1; 




4. β1-integrin deletion induces tumor cell 
dissemination and reduction of tumor burden 
 
 70
4.3.3. Loss of β1-integrin induces tumor cell dissemination into lymphatics  
 
Previously, we have reported that NCAM- deficient insulinomas show increased 
tumor associated lymphangiogenesis (Crnic et al., 2004), as well as tumor tissue 
disaggregation and increased metastasis (Cavallaro et al., 2001; Perl et al., 1999). To 
investigate whether loss of β1-integrin leads to increased lymphangiogenesis, we analyzed 
sections of 11-13 weeks old mice for the presence of lymphatic vessels using the α-LYVE-1 
antibody (Banerji et al., 1999). Tumors were divided into five groups according to the degree 
of lymphatic vessel lining (no lymphatic vessels = 0 %, 1-10 %, 10-25 %, 25-50 % or > 50 % 
of tumor perimeter covered by lymphatic vessels, Figure 4). Statistical analysis revealed that 
no significant changes in lymphangiogenesis were observed for any group. Moreover, as 
asseyed by immunohistochemical staining, VEGF-C levels are not altered in β1-integrin 
deleted tumors (data not shown). We conclude that loss of β1-integrin function does not 
















Figure 4: Lymphatic lining of RT2;β1fl/fl and RCre;RT2;β1fl/fl tumors 
RT2;β1fl/fl (white bars) and RCre;RT2;β1fl/fl (black bars) tumors were categorized according to the 
degree of lymphatic coverage of the tumor circumference (see text). Statistical analysis (unpaired t-
test) indicated that differences within groups are not statistically significant. 
 
 
Ablation of NCAM in the Rip1Tag2 model leads to a severe change in tumor 
architecture, namely marked tissue disaggregation and the appearance of hemorrhagic lacunae 
(Cavallaro et al., 2001; Xian et al., 2006) Extensive biochemical analysis of NCAM-/- tumor 
cell lines revealed that NCAM-deficient cells have an impaired capability to adhere to extra-
cellular matrix in vitro, arising from the lack of NCAM dependent, FGFR-4 mediated 
activation of β1-integrin. We thus investigated if deletion of β1-integrin in this tumor model 
induces tissue disaggregation by analyzing H&E stained sections of RT2;β1fl/fl and 
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RCre;RT2;β1fl/fl tumors. We did not observe significantly increased appearance of 
hemorrhagic lacunae and therefore tissue disaggregation within RCre;RT2;β1fl/fl tumors. 
Interestingly though, during the analysis of sections stained for LYVE-1 (see above), we 
found disseminated tumor cell clusters enclosed by lymphatic vessels in 60% of 15 analyzed 
RCre;RT2;β1fl/fl mice and only in 7.7% of 12 control mice (Figure 5A and 5B). The tumor cell 
clusters were predominantly found in close vicinity to the tumors (Figure 5C, left panel) or 
tumor edges (Figure 5C, right panel). Importantly, immunohistopathological analysis did not 
reveal the occurrence of metastases. 
 
 
Figure 5: Disseminated tumor cell clusters in RCre;RT2;β1fl/fl mice 
Percent of mice (panel A) showing disseminated tumor cell clusters and average number of 
disseminated tumor cell clusters per mouse (panel B) in RT2;β1fl/fl (white bars) and RCre;RT2;β1fl/fl 
(black bars) mice. N, number of analyzed mice; ***, P<0.02; C: LYVE-1 staining (brown, big 
arrowheads) of RCre;RT2;β1fl/fl tumors. Circulating tumor cell clusters are highlighted with small 
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4.3.4. β1-integrin-deficient β tumor cells exhibit proliferation deficiencies 
 
To investigate how the deletion of β1-integrin contributes to the reduction of tumor 
burden and might limit the metastatic potential of disseminated tumor cells, we established 
cell lines from RCre;RT2;β1fl/fl experimental as well as RT2;β1fl/fl control tumors. PCR 
analysis confirmed the presence of two floxed β1-integrin alleles in control cells (βTifl/fl) and 
two deleted alleles in cells derived from experimental tumors (βTi∆, Figure 6A, upper panel). 
FACS analysis demonstrated that βTi∆ cells lost β1-integrin expression. Cell lines derived 
from RT2;NCAM+/+ (βT2) and RT2;NCAM-/- (βTN2) tumors (Cavallaro et al., 2001), both 
carrying the wild type β1-integrin alleles, showed β1-integrin expression levels comparable to 
those of the βTifl/fl cell line (data not shown). Importantly, NCAM levels in these cell lines 
vary in that βT2 cells express very high levels of NCAM, whereas in the βTifl/fl and βTi∆  













Figure 6:  Cell lines derived from RT2;β1fl/fl and RCre;RT2;β1fl/fl tumors  
A, top: Genotyping of cell lines derived from RT2 (βT2), RT2;β1fl/fl (βTifl/fl),  RCre;RT2;β1fl/fl (βTi∆) 
and RT2;NCAM-/- (βTN2)  tumors by PCR analysis. βT2 and βTN2 both carry the wild type β1-
integrin alleles (wt), βTifl/fl carry the conditional alleles (fl) and almost all βTi∆ cells have undergone 
recombination and therefore mainly carry the deleted (∆) alleles. A, bottom: Western Blot analysis of 
NCAM levels in βT2, βTifl/fl, βTi∆  and βTN2 cells. NCAM levels in βT2 cells are very high, whereas 
βTifl/fl and βTi∆ cells have low NCAM expression. βTN2 served as negative control. B: β1-integrin 
surface expression levels of βTifl/fl (black line) and βTi∆ (red line) cells, assayed by FACS analysis. 
βTi∆ cells have no more β1-integrin surface expression.  Dashed line, control (unstained cells);   
  
 
Using adhesion of cells to collagen IV (a specific substrate for β1-integrin) as an 
assay for β1-integrin activation, we have previously shown that activation of β1-integrin is 
abolished in NCAM-deficient βTN2 cells and can be re-established by re-introducing NCAM 
(Cavallaro et al., 2001).  We thus compared the adhesion capabilities of βTifl/fl and βTi∆ cell 
lines to those of βT2 cells in the presence or absence of NCAM. Equal amounts of cells were 
seeded onto either uncoated or collagen IV coated 96-well plates and cells were allowed to 
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adhere for 90 min. Intrinsic adhesion to collagen IV of the βTi∆ cell line was very low   
(6.76 % of βT2, Figure 7) and adhesion could not be increased significantly by re-introducing 
NCAM140 (9.86%). Similarly, adhesion of Mock-transfected βTifl/fl cells was only 16% of 
βT2 cells, however, re-introducing NCAM140 significantly stimulated adhesion to the β1-
integrin specific ligand collagenIV (16% Mock transfected vs. 32% NCAM 140 transfected 
cells) but not to uncoated plastic. Interestingly, even in βT2 cells that express very high 
amounts of NCAM, adhesion could be further stimulated by NCAM transfection.  Thus, 
















Figure 7: Adhesion assay of β tumor cells 
Mock-transfected (clear bars) or NCAM140 transfected (dotted bars) β tumor cells were seeded on 
either uncoated (grey bars) or collagen IV coated (red bars) dishes. Adherent cells were counted as 
described in Materials and Methods. Adhesion of Mock-transfected βT2 cells to collagen was taken as 
100% for reference.  ***: increase in adhesion is statistically significant (P<0.003, unpaired t-test). 
  
Since deletion of β1-integrin in RT2 tumors leads to a reduction of tumor volumes, 
decreased proliferation and apoptosis, we analyzed growth rates of β1-integrin deleted β-
tumor cells in comparison to control cells. As shown in Figure 8, βT2, βTN2 and βTifl/fl 
display very similar growth curves and linear regression curves have comparable slopes 
(0.0024 for βT2, 0.0025 for βTifl/fl and 0.0027 for βTN2). Growth of the β1-integrin deleted 
cell line (βTi∆) however, was significantly slower (0.0014, P < 0.0001, unpaired t-test of 
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Figure 8: Growth curves of β tumor cells in 2D-culture 
MTT assay of β-tumor cell lines. Absorption as an indirect measure for cell counts is plotted against 
the time after seeding cells (0h). Linear regression curves were calculated and are displayed for each 
cell line. *** indicates that decrease in growth rate of βTi∆ cells is statistically significant compared 
to all other cell lines (P<0.001, unpaired t-test of linear regression curves) 
 
 
Since integrins are the major receptors for extracellular matrix (ECM), we 
hypothesized that culturing βTifl/fl and βTi∆ tumor cells in a 3D matrigel culture could 
reflect the potential effects of β1-integrin deletion on cell growth closer to an in vivo system. 
In fact, already two days after seeding the cells in matrigel, differences in cell and cell-cluster 
shape became apparent: many of the plated βTifl/fl cells formed filopodia-like protrusions 
(Figure 9A, left panel) some of them longer than the cell/cell clusters diameter (Figure 9A). 
In contrast, βTi∆ cells did not seem to out-grow cell protrusions and generally looked rather 
unhealthy under this growth conditions (Figure 9A, right panel. Quantification of this effect 
by counting cells with or without protrusion in a defined volume revealed that more than 70% 
of the counted βTifl/fl cells developed protrusions, whereas not a single of the β1-integrin 
deleted cells showed formation of these structures. One week after plating, all βTi∆ cells 
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Figure 9: Growth of  
βTifl/fl and βTi∆ cells in 
matrigel 
A: Pictures of cells two 
days after seeding them in 
a 3D matrigel culture. β1-
integrin expressing 
βTifl/fl cells (left panel) 
develop filopodia or 
neurite-like protrusions, 
in contrast, βTi∆ (right 
panel) cells do not 
produce these structures 
and do not seem to 
proliferate. B: 
Quantification of 
protrusion formation of 




4.3.5. β1-integrin expression, but not NCAM is necessary for metastasis formation 
 
We next asked whether cell lines carrying the β1-integrin or NCAM deletion were 
able to grow and form tumors and metastases in vivo. Equal amounts of tumor cell 
suspensions of βTifl/fl, βTi∆ , βTN2 and βT2 cells were injected subcutaneously into 
immune-competent C57 mice. After five weeks, mice were sacrificed and tumor incidence, 
tumor size and tumor volumes were determined (Figure 10A and 10B). Tumors were formed 
in 12,5% of all βT2 injected sites and in 37,5% of all βTifl/fl injected sites. The average size 
of tumors from βT2 cells was 293,35 +/- 129.4 mm3 as compared to 174,66 +/- 53.11 mm3 for 
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tumors arising from βTifl/fl cells. In contrast, βTi∆ and βTN2 cells did not give rise to any 
tumors. 
 
Figure 10: Ectopic transplantation of β tumor cell lines 
A: Average volumes of tumors arising from either βT2 or βTifl/fl cells (see text and Materials and 
Methods). B: tumor incidence in C57 mice injected with the indicated cell lines. 16 sites were injected, 
the percetage of sites with tumors is displayed. 
 
To assess the metastatic potential of the cell lines, we injected equal amounts of cells 
into the tail vein of athymic nude mice. After four weeks of incubation, mice were sacrificed. 
Pancreata, lungs and livers of all mice were isolated, organs were fixed in PFA and sections 
were cut through the whole organs. As shown in Table 3, by immunopathological 
investigation by H&E staining, metastases to either the lungs and/or the livers were identified 
in all β tumor cell lines except for βTi∆, lacking β1-integrin expression. 
 
 
Table III: Intravenous injection of β-tumor cell lines 
 
Cell line Number of injected sites Number of mice with 
metastases 
Site of metastasis 
βT2 5 4 lung/liver 
βTifl/fl 5 3 lung 
βTN2 5 4 lung/liver 




These results indicate that depletion of NCAM and therefore β1-integrin activity in 
βTN2 cells diminishes tumor formation but does not interfere with metastasis formation. 
However, total loss of β1-integrin function results in an incapability of βTi∆ cells to form 
tumors and metastases in vivo indicating a crucial role of β1-integrin in these processes. 
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4.4.1. β1-integrin function is required for proper islet development 
 
We show here that deletion of β1-integrin in the β cells of pancreatic islets of 
Langerhans leads to disturbance in proper islet-cell segregation. Interestingly, a similar 
phenotype was observed in NCAM-deficient islets (Esni et al., 1999) and islet expressing a 
dominant negative version of E-cadherin (Dahl et al., 1996), indicating that both cell adhesion 
molecules play an important role in proper cell sorting. Previously, our in vitro studies 
showed that NCAM dependent FGFR signaling leads to β1-integrin activation (Cavallaro et 
al., 2001).  Therefore, one might speculate that this signaling pathway is involved in the 
sorting process during islet development.   
 
 
4.4.2. β1-integrin outside-in signaling but not NCAM mediated inside-out signaling is 
required for metastasis formation 
 
Tissue disaggregation and lymphangiogenesis, have been shown to be sufficient on 
their own to induce the formation of lymph node metastases. Interestingly, in RCre;RT2;β1fl/fl 
mice, tumor cell clusters were found disseminated into lymphatic vessels. However, the fate 
of the disseminated tumor clusters in RCre;RT2;β1fl/fl mice is not clear. They are not able to 
form metastases, since none could be observed in RCre;RT2;β1fl/fl mice, neither in the local 
lymph nodes, nor in other organs. In addition RCre;RT2;β1fl/fl tumor-derived cells do not form 
metastasis when injected into nude mice. This phenomenon does not seem to be linked to the 
adhesive defects of β1-integrin-deleted cells, since βTN2 cells, which are deficient for β1-
integrin mediated adhesion, can still metastasize. Rather, the proliferation deficiency 
observed in the primary tumor and in the RCre;RT2;β1fl/fl tumor-derived cells might be the 
main reason for the incapability to grow metastasis. However, we cannot exclude that the 
clusters are not circulating at all since these cells are very difficult to detect in the circulatory 
system. 
Integrins have been shown to be bi-directional signaling molecules (Hynes, 2002). 
Inside-out signals activate integrin-mediated adhesion to ligands such as collagen, laminin 
and others. On the other hand, outside-in integrin signaling results in cellular responses such 
as proliferation, survival or apoptosis. βT2 cells have very high NCAM levels and hence 
show high levels of β1-integrin activation. βTN2 cells have lost NCAM-dependent, inside-out 
activation of β1-integrin but still express the protein, allowing reception of outside-in signals. 
In the contrary, βTi∆ cells lost both integrin functions. Using these established cell lines in 
adhesion, proliferation and transplantation assays allowed for the discrimination of the role of 
adhesive (inside-out) and growth promoting (outside-in) integrin functions. The cell-line-
derived data are summarized in Table 4.  
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Table IV: Summary of data derived from experiments on β tumor cell lines  
 
 NCAM exp Col IV stim. 2D 3D s.c. i.v. 
βT2 +++ + +  + * + + 
βTifl/fl + + +        + + + 
βTN2 -       +*** +   + * - + 
βTi∆ + - -/+ - - - 
 
NCAM exp, NCAM expression levels of cell lines, +++: high levels, +, low levels, - no expression; Col 
IV stim., adhesion to collagen IV stimulatable by NCAM transfection, +: stimulatable, -: not 
stimulateble; 2D, growth of cell lines in 2D cultures, +: cells growing; -/+: cells grow slower; 3D, 
growth of cell lines in matrigel, +: cells grow, -: cells cannot grow; s.c.,  tumor growth  after 
subcutaneous injection, +: tumors are formed, -: no tumor formation; i.v., metastasis formation after 
intravenous injection, +: metastases formed, -: no metastases formed; * data not shown; *** shown in 
(Cavallaro et al., 2001)  
 
Deletion of β1-integrin clearly reduces the proliferative capability of cells in vitro as 
well as in vivo, which we have shown in 2D and 3D growth assays and subcutaneous 
transplantation experiments. Interestingly, βTN2 cells that have lost NCAM dependent 
inside-out activation cannot form tumors when injected subcutaneously, but are still capable 
of metatasis formation when injected intravenously into nude mice. In contrast, βTi∆ cells 
that can receive neither inside-out nor outside-in signals, do not grow tumors or metastasize at 
all upon transplantation. This suggests that expression of β1-integrin is required to transduce 
outside-in signals that allow cells to survive and proliferate at distant sites.  
One therefore might speculate that tumor cells that have reduced adhesive properties 
due to disturbances in the inside-out signaling to β1-integrin (such as for example 
RT2;NCAM-/- tumors) disseminate and therefore more easily enter routes for metastasis 
formation. Since they still express β1-integrin, the protein is available to transduce pro-
proliferative outside-in signals. In contrast, in RCre;RT2;b1fl/fl mice β1-integrin expression is 
lost in 40% of the tumor cells. These cells disseminate but, lacking β1-integrin, cannot receive 
outside-in signals that allow them to proliferate and eventually metastasize. This hypothesis 
could be tested by interfering with β1-integrin function in RT2;NCAM-/- tumors. We are 
currently intercrossing RCre;RT2; β1fl/fl and RT2;NCAM-/- mouse strains. If our hypothesis 
holds true, we would expect no more metastases to be formed. 
 
 
4.4.3. Loss of β1-integrin reduces tumor burden potentially by inducing senescence 
 
We found that tumor volumes, but not tumor incidence are reduced in β1-integrin 
depleted tumors, which might be an indication that β1-integrin function is required for later 
stages of tumor progression. When cells are properly attached to the right ECM, they receive 
signals allowing them to survive and proliferate. In contrast, dislocation of cells, or total loss 
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of ECM anchorage induces anoikis, driving cells into apoptosis. The main mediators of these 
signaling processes are integrins, communicating and influencing cell behavior via outside-in 
signaling. Hence we suspected that the reduced tumor burden in β1-integrin-deleted tumors 
might have been due to the induction of anoikis. However, the number of apoptotic cells and 
proliferating cells even decreased in RCre;RT2;β1fl/fl tumors. This result suggests that anoikis 
is not induced in the tumors. Rather the general metabolic activity seems to be reduced. Such 
a change in metabolic activity can be associated with quiescence, senescence and tumor 
dormancy. Senescence-associated β-Galactosidase (SA-β-Gal) is expressed in senescent cells 
and is therefore frequently used as a marker. It can be specifically detected at pH 6 via 
histochemistry (Dimri et al., 1995). In contrast, bacterial β-Galactosidase is most active at 
pH7.5. Since the β1fl/fl mice are constructed in a way that, upon efficient recombination, a 
bacterial β-Galactosidase reporter comes under the control of the β1-integrin promoter, and 
because bacterial β-Galactosidase also displays activity at pH 6, we could not test for SA-β-
Gal in these mice. However, we recently obtained an alternative mouse line with conditional 
β1-integrin alleles designed in a different way, not carrying a β-Galactosidase reporter (β1EII 
mice). We have intercrossed these mice to the RT2 tumor model giving rise to 
RCre,RT2;β1EII mice. Importantly, when we investigated sections of tumors derived from 
RCre;RT2;β1EII mice, we could detect positive staining for SA-β-Gal (data not shown). This 
suggests that deletion of β1-integrin in RT2 tumors reduces tumor burden by inducing 
senescence. We are currently investigating the expression of other senescence-associated 
markers, such as the formation of heterochromatin protein-1γ (HP-1γ) containing 
heterochromatin foci, in β1-integrin-deficient tumors. To our knowledge, this is the first time 
that integrin function is associated with senescence. 
Interestingly, outside-in signals from integrins are mainly transduced via the focal 
adhesion kinase (FAK) and it has been shown that inhibition of FAK signaling in human 
carcinoma cell lines induces quiescence in vivo. This suggest that FAK activity might be 
reduced in RCre;RT2;β1fl/fl tumors and in β1-integrin deleted cell lines. It will be of 
importance to investigate the quality of the focal complexes in our cellular and mouse 
systems in the future.  
Targeting β1-integrin function in tumors might induce senescence and interfere with 
metastasis formation, thus β1-integrin inactivating antibodies might represent a novel 
approach for cancer treatment. Consistent with this notion, studies on cell lines confirmed 
their potential efficacy since blocking β1-integrin could revert the malignant phenotype of a 




4.4.4. Loss of β1-integrin induces tumor cell cluster dissemination but not 
lymphangiogenesis 
 
It has been shown that increased tumor lymphangiogenesis correlates positively with 
the incidence of metastases (Cao, 2005). Among the factors that contribute to 
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lymphangiogenesis are VEGF-C and VEGF-D. Transgenic expression of these factors 
induces lymphangiogenesis and metastasis in the Rip1Tag2 tumor model (Mandriota et al., 
2001,  Kopfstein et al., submitted). Interestingly, in RT2;NCAM-/- tumors these two ligands 
were found up-regulated. RT2;NCAM-/- tumors also show severe tissue disaggregation and 
the appearance of large lacunae, filled with hemorrhagic fluid, potentially leading to increased 
interstitial fluid pressure. One controversial theory hypothesizes that tumor associated 
lymphangiogenesis is induced to reduce the tumors interstitial fluid pressure. Since the 
observed tissue disaggregation is potentially caused by the reduced capability of β cells to 
adhere to ECM substrates, we hypothesized that the inactivation of β1-integrin might lie 
upstream of the induction of lymphangiogenesis in RT2;NCAM-/- mice. However, our results 
show that β1-integrin deletion does not lead to tumor lymphangiogenesis. Thus, it seems that 
the increased lymphangiogenesis observed in RT2;NCAM-/- mice is not directly due to a 
defect in the β1-integrin function.  
A recent report linked the appearance of hemorrhagic lacunae and the concomitant 
tissue disaggregation phenotype in NCAM-/- tumors to decreased pericyte recruitment to 
endothelial cells. In this study, it was demonstrated that loss of NCAM in β-cells negatively 
influenced pericyte-endothelial cell-cell interactions, which results in increased blood vessel 
leakage. Furthermore, pericyte deficiency per se caused haematogenous spreading of tumor 
cells and metastasis formation (Xian et al., 2006).  
Deletion of β1-integrin in the RT2 model did result in a disaggregation phenotype, yet 
distinct to that observed in NCAM-deficient tumors. In RCre;RT2;β1fl/fl mice, tumor 
architecture per se was not altered, but clusters of tumor cells disseminated into lymphatic 
structures were found. Disseminated tumor cells are also found in NCAM-deficient mice, 
suggesting that in RT2;NCAM-/- tumors two different mechanisms are employed, impaired 
pericyte recruitment  and loss of cell matrix adhesion. Both of them result in tumor cell 
dissemination. In the first one, loss of NCAM in β cells seems to induce disaggregation 
indirectly by affecting blood vessel stability. In the second one, intrinsic adhesive properties 
of β cells are affected upon NCAM ablation as we could show by the study of the loss of β1-
integrin activation and function. This leads to the tumor cell cluster dissemination described 
in RCre;RT2;β1fl/fl mice and we think this reflects an additional, alternative pathway leading 
to tumor dissemination in NCAM-negative tumors. Still, it is not clear how the disseminated 
cells in RCre;RT2;β1fl/fl mice enter the lymphatics. Lymphatic vessels are structurally 
different to blood vessels and are thought to be more permeable, which may be an explanation 
.  
Taken together, our results support our previous findings that loss of β1-integrin 
function in β cells reduces their cell-matrix adhesion and causes tumor cell dissemination. 
Our data furthermore show that the inactivation of β1-integrin does not lie upstream of the 
induction of lymphangiogenesis since RCre;RT2;β1fl/fl  tumors do not display increased 
lymphatic vessel coverage. Further experiments are needed to unravel the pathways and 
mechanisms leading to the induction of lymphangiogenesis and lymph node metastasis in 
NCAM deleted tumors. 
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5. General discussion 
 
In this work we provide evidence that NCAM binds to all members of the FGFR 
family as well as to PDGFRα and PDGFRβ. Based on the observation that RTKs lacking Ig 
domains in their extracellular domains cannot bind to NCAM, we suggest that the presence of 
an Ig domain is a requisite for NCAM binding. If this holds true, one might expect to identify 
additional, if not all Ig-domain RTKs, as NCAM binding partners.  
So far, the role of NCAM in modulating RTK signaling has been mainly studied with 
FGFR signaling in neurons, and its effects were primarily thought to be pro-stimulatory 
(Povlsen et al., 2003). Here, we broaden NCAMs “place of action” to additional RTKs in 
non-neuronal tissues, such as endocrine and fibroblastic cells. Importantly, we furthermore 
identify a novel way of action for NCAM, since we demonstrate that it can exert also 
inhibitory functions on RTKs. In many human cancers, both a reduction or an increase of 
NCAM levels are correlated with increased malignancy which might be a reflection of 
NCAMs dual role in modulating RTK signaling. 
The Rip1Tag2 tumor model is one example where loss of NCAM correlates with 
increased malignancy. NCAM-deficiency in these tumors leads to tissue disaggregation, 
induction of lymphangiogenesis and the formation of metastases (Perl et al., 1999; Crnic et 
al., 2004; Cavallaro et al., 2001). One target of NCAM signaling in β tumor cells is β1-
integrin. We show here that loss of β1-integrin is sufficient to induce tumor cell 
dissemination. In contrast, lymphangiogenesis induced by NCAM-deficiency is independent 
of β1-integrin function and probably relies on an alternative NCAM dependent pathway. 
Induction of lymphangiogenesis alone has been shown to induce metastasis (Mandriota et al., 
2001), however, interfering with lymphangiogenesis in NCAM depleted tumor mice only 
partially blocked the formation of metastases (Crnic et al., 2004), indicating that an additional 
mechanism contributes to the metastatic phenotype. This additional feature might be tissue 
disaggregation that results from impaired pericyte recruitment to blood vessel endothelial 
cells in NCAM knock out tumors (Xian et al., 2006), since lack of pericyte recruitment also 
resulted in metastasis formation. Importantly, tissue disaggregation induced by blocking β1-
integrin function did not give rise to metastases. Furthermore, tumor sizes were reduced in β1-
integrin deleted tumors, probably due to the induction of senescence. These findings suggest 
β1-integrin to be a more promising target for the intervention with metastasis formation in 
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